Toward a Recombinant Adeno-Associated Virus Origin of Replication by Hewitt, Frank Curtis.
Toward a Recombinant Adeno-Associated Virus Origin of 
Replication 
 
 
 
 
 
F. Curtis Hewitt 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Curriculum of Genetics and Molecular Biology 
 
 
 
 
Chapel Hill 
2009 
 
 
 
 
Approved By: 
Advisor: Richard J. Samulski 
Reader: Christina Burch 
Reader: Blossom Damania 
Reader: Tal Kafri 
Reader: Dale Ramsden 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©2009 
F. Curtis Hewitt 
ALL RIGHTS RESERVED 
 iii 
 
 
 
 
 
Abstract 
F. Curtis Hewitt 
Toward a Recombinant Adeno-Associated Virus Origin of Replication 
(Under the direction of Richard Jude Samulski) 
 
 Adeno-associated virus (AAV) is widespread throughout the human population. Many 
of the traits responsible for this ubiquity also make AAV an exceptional gene delivery vehicle. 
However, the widespread nature of AAV creates the risk that recombinant AAV vectors could 
be mobilized into unintended tissues or the general population by wild type (wt) AAV 
replication machinery. Alarmingly, the majority of characterized AAV serotypes are capable of 
rescuing and replicating the AAV2-based vectors currently used in AAV clinical trials.  
There are a number of potential methods to prevent AAV vector mobilization. The 
origin of replication from a less prevalent human AAV serotype or a non-human serotype 
would decrease, but not eliminate, the risk of mobilization. Ultimately, AAV vectors must 
utilize an origin of replication incompatible with the Replication (Rep) proteins of any 
naturally occurring AAV serotype. Unfortunately, the nature of the AAV origin, the inverted 
terminal repeat (ITR), has been a barrier to understanding the mechanisms of replicative 
specificity necessary to synthesize a novel origin.  
By generating a panel of chimeric and mutant ITRs and Rep proteins between two 
serotypes of AAV, we have mapped two independent DNA-protein interfaces required to 
generate replicative specificity. In vivo replication assays demonstrated that for AAV2, three 
residues in the Rep active site are required to make specific contacts with the nicking site of 
ITR2. AAV5 has a unique interaction between a 12 nucleotide extended Rep binding element 
 iv 
and a 49 amino acid region of Rep5 containing two DNA binding interfaces. Structural models 
display significant differences between serotypes in these regions.  Understanding the 
separation of these elements led to the creation of a recombinant origin of replication with 
properties independent of either parent serotype. This novel origin stands to prevent AAV 
vector mobilization and expand our understanding of the basic mechanisms of AAV replication.  
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Chapter 1: Introduction 
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1A. AAV Virology 
Adeno-associated virus (AAV) was discovered as a contaminating factor in 
adenoviral (Ad) preparations over 40 years ago (2). The potential of AAV for gene delivery 
has been the driving force behind research of the virus since then, due in large part to its lack 
of pathogenicity. While the requirement of a helper virus to replicate AAV once led to the 
label of “defective virus,” today the elegant and complex nature of the virus is better 
understood. Indeed, AAV has succeeded evolutionarily to such a great degree that it is now 
ubiquitous in many vertebrate species including our own.  
The 4.7kb single strand (ss) AAV genome is relatively simple (Figure 1). The 
genome is flanked by T-shaped inverted terminal repeats (ITRs) approximately 150 base 
pairs (bp) in length (4). Roughly half of the genome encodes four non-structural replication 
(Rep) genes from a single open reading frame (orf) via alternative splicing and an alternative 
transcriptional start site (58, 88). The p5 and p19 promoters drive transcription of the Rep 
gene products and harbor Rep binding sequences which allow Rep to auto-regulate its 
expression. The other half of the genome encodes three capsid (Cap) proteins from the same 
orf by virtue of alternative splicing. The Cap genes are transcribed from the p40 promoter 
which is trans-activated by the Rep protein (69).  
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Figure 1. Organization of the AAV genome. 
Two T-shaped ITRs flank the AAV genome. Four different Rep proteins (Rep78, Rep68, 
Rep52, and Rep40) are produced from the p5 and p19 promoters and alternative splicing. The 
p40 promoter drives expression of the three Cap proteins (VP1, VP2, and VP3) which are 
produced by alternative splicing. 
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The viral ITRs are the only cis-elements required for replication and encapsidation of 
the genome. Sequences within the ITR are bound site-specifically by Rep. The ATP-
dependent Rep helicase unwinds the ITR structure allowing the formation of a secondary 
hairpin, or “nicking stem” which is nicked by Rep in order to catalyze AAV replication (9). 
The complex secondary structure and high G-C content of the ITR make it highly 
recombinogenic. These features are necessary for the latent phase of the virus as well as for 
efficient correction or repair of mutated ITRs upon entry into the lytic phase.   
The AAV Rep proteins have multiple functions critical to the AAV replicative cycle. 
The N-terminus contains two separate DNA binding interfaces which bind specific sequences 
within the ITR. The Rep DNA binding domain also binds specifically to the three AAV 
promoter sequences as well as specific Ad promoters. This domain also contains the active 
site of the molecule. The active site interacts with the nicking stem of the ITR and contains 
the nucleophilic tyrosine molecule responsible for creating a site-specific nick (86). The C-
terminus of Rep contains an oligomerization domain that participates in Rep multimerization 
on the ITR. The C-terminus also possesses residues which bind specifically to the viral 
capsid in an interaction required for encapsidation of the genome. Additionally, the C-
terminus harbors an ATP-dependent SF3 DNA helicase required for both replication and 
encapsidation (20). It is believed that the Rep helicase “motor” bound to the pre-constructed 
capsid acts to thread the viral genome through a pore at the 5-fold axis of symmetry (43). The 
N-terminal DNA binding/nicking domain is contained exclusively by the large Rep proteins, 
Rep78 and Rep68 (Figure 1). These large Reps are necessary to catalyze replication due to 
their exclusive interaction with the ITR. Two small Rep proteins, Rep52 and Rep40, 
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transcribed from the p19 promoter, lack this domain. While these small Rep proteins are not 
necessary for replication, they are required for efficient encapsidation (43).  
Sixty of the AAV Cap proteins come together to form a 22 nm diameter particle with 
T=1 icosahedral symmetry. Three different Cap proteins are produced: VP1, VP2, and VP3 
(Figure 1). An assembled capsid consists of these proteins in a 5:5:50 ratio, respectively. 
Encapsidation of the genome is believed to occur through a pore in the center of one of the 
twelve pentamers which make up the capsid (8). This pore is also thought to allow the 
extrusion of the unique N-terminus of the VP1 and VP2 subunits. The N-terminus of VP1 
contains a phospholipase domain required for transduction and is only externalized after the 
virion has been internalized into the endosome (26, 110). The N-terminus of VP1 and VP2 
harbor nuclear localization sequences necessary to target the virion to the nucleus for 
delivery of the genome (87). VP3 is the major structural protein and contains the receptor 
binding motifs required for cell binding and entry. Changes in receptor binding are 
responsible for the wide range of tissue tropisms of different AAV serotypes. Heparan sulfate 
and N- or O-linked sialic acid are the major cell receptors for the majority of characterized 
AAV serotypes (99). Many of the specific regions and residues involved in receptor binding 
have been identified and can be altered via rational mutagenesis or directed evolution 
techniques to specifically target new cell types (54).  
AAV replication requires co-infection by a helper virus or cellular stress (14, 50, 64). 
Ad typically serves as the wt helper virus for AAV, though Herpes Simplex Virus (HSV) can 
also complement AAV replication. AAV has evolved intricate mechanisms of viral latency 
due to its dependence on a helper virus for replication. The large Rep proteins auto-regulate 
both the p5 and p19 promoters (Figure 1) (47, 69). In the absence of helper, this auto-
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regulation prevents Rep transcription and keeps the virus in a latent state. Upon 
superinfection by Ad, four early genes are required for AAV replication: E1A, E1B, E2A, 
and E4. E1A and E4 are required for transactivation of the AAV promoters. E1B and E2A 
are involved in aiding mRNA transport as well as stalling the cell cycle to allow 
uninterrupted viral production (11, 12, 13, 48, 51, 72, 78). Additionally, Ad virus-associated 
(VA) RNA is required to prevent the interferon host cell shutoff mechanism of translation. 
Ultimately, the presence of these helper genes (or cytotoxic stress) leads to the alteration of 
auto-regulatory Rep complexes, transforming them into trans-activators of all three AAV 
promoters (69). This leads to Rep-catalyzed replication and encapsidation of the genome.  
Because not every cell infected with AAV will also be infected with helper virus, 
AAV is highly efficient at ensuring long-term persistence of its genome. Post infection, 
genomes typically circularize or form higher-order concatemers (18, 83, 101). In non-
dividing tissues, these genomes have been shown to persist in an episomal state indefinitely 
(23). However, non-replicating episomes in dividing tissue are diluted and eventually lost in 
a manner similar to plasmid DNA. For that reason, long term persistence of AAV in dividing 
cells requires integration of the viral genome into the host chromosome. The recombinogenic 
ITRs contribute to a low level of random integration (75). Additionally, AAV is unique 
among animal viruses in the ability to direct its genome to integrate site-specifically into the 
host chromosome (14, 45, 80). The AAVS1 site on human chromosome 19 contains a Rep 
binding element and nicking site enabling Rep2 to direct viral genomes into that site (97). 
Due to the likelihood of losing all or part of the ITR during recombination, AAV can 
efficiently “gene correct” its ITRs, repairing a deleted or mutated ITR using the opposite ITR 
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as a template (79). This ability to self-repair the ITR is critical for the rescue of an AAV 
provirus entering the lytic phase.  
1B. AAV Replication  
The AAV ITRs are critical for nearly every aspect of the viral life-cycle. As they are 
the only cis-element required for replication and encapsidation, a recombinant AAV (rAAV) 
vector can be efficiently produced as long as the Rep and Cap genes are provided in trans 
(102). As the ss genome enters the nucleus, the secondary structure of the ITR provides a free 
3’ hydroxyl to act as a primer for synthesis of the second strand. This results in a ds genome 
capable of undergoing transcription (Figure 2A-C; 33). This replicative intermediate is 
known as a monomer (m).  In the absence of Rep, the ITR with a free 3’ hydroxyl can prime 
synthesis of the entire molecule again. This results in a dimmer (d) molecule (Figure 2I). 
This process can continue in the absence of Rep, allowing higher-order intermediates to form 
until Rep acts to resolve the ITRs.  
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Figure 2. Model of AAV genomic replication. 
The AAV genome enters the nucleus as a single strand molecule with the exception of the 
ITRs (A). The ITR acts to prime second strand synthesis (newly synthesized strand shown in 
red; B). This leads to duplication of the opposite ITR and transcription of viral genes (C). 
Rep binds (D) and nicks (E) the closed ITR allowing synthesis of the remainder of the 
genome (F). The fully replicated genome (G) can be displaced by the Rep helicase or by the 
subsequent synthesis of a new second strand (H). Alternately, in the absence of Rep, a 
dimeric genome can be synthesized using the 3’ hydroxyl of the open ITR as a primer (I).  
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In the presence of Rep, the large Rep proteins (78 and 68 kDa) are responsible for 
binding site-specifically to the ITR on both the tetrad GAGY repeat known as the Rep 
binding element (RBE) and to the tip of one of the hairpin stems (RBE’, Figure 2D; 10, 76). 
Rep molecules multimerize on the ITR, binding every four nucleotides along the RBE. Rep is 
thought to bind as two hexamers in a head-to-head orientation, although there is evidence 
that it may bind as two octamers or may only require dimerization for function (55, 60, 84, 
85, 93). Upon ITR binding, the ATP-dependent SF3 helicase in the C-terminus of Rep 
unwinds the DNA, leading to the formation of an internal hairpin (Figure 4). This nicking 
stem contains the terminal resolution site (trs) and specific nicking site of the ITR (9). After 
nicking, Rep remains covalently attached to the 5’ end of the ITR. The liberated 3’ hydroxyl 
primes synthesis through the ITR to complete synthesis of the genome (Figure 2E-G; 70). 
Fully replicated genomes can undergo subsequent rounds of replication or can be 
encapsidated (Figure 2H). Unlike many autonomous parvoviruses, the (+) and (-) polarity 
strands are packaged interchangeably during AAV encapsidation (5). 
Polymerase (Pol) δ has been identified as the host polymerase responsible for AAV 
second strand synthesis. As with normal Pol δ function, PCNA and RFC are also critical for 
second strand synthesis. Once the second strand has been synthesized, the genome typically 
circularizes or concatemerizes in a process which also utilizes host cell machinery. Cellular 
repair machinery recognizes the ITR as a double strand break repair intermediate. This 
results in the recruitment of Rec Q helicases, the MRN complex, as well as ATM and other 
DNA repair machinery which are necessary for circularization or contatemerization of the 
AAV genome (17). 
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As an alternative to second strand synthesis, because both (+) and (-) strands are 
encapsidated, it is possible that AAV genomes could anneal after infection. While wt AAV 
likely does not infect cells at high enough titer for genomes to anneal efficiently, this 
pathway might occur in assays utilizing AAV as a vector when as many as 100,000 vector 
genomes (vg)/cell are administered. Because synthesis of the second strand is the major rate-
limiting step for wt AAV and rAAV infections, vector genomes have been designed to 
bypass this step. These vectors (termed self-complimentary) utilize one wt ITR and one ITR 
with a deletion preventing Rep nicking (62). Because of the mutant ITR, self-complimentary 
(sc) vectors package a ds genome with the closed, mutant ITR acting as a hinge to allow self-
annealing and transcription of the genome without second strand synthesis. As a result, 
scAAV vectors have a quicker onset of transcription and subsequent expression of the 
transgene. Due to the packaging constraints of AAV, however, this requires sc vectors be no 
larger than 2.4 kb in length. Thereby, scAAV vectors can not be used for vector cassettes 
requiring the entire 4.7 kb capacity of AAV. 
1C. Evolutionary Relationships of AAV Serotypes 
AAV belongs to the family Parvoviridae. Historically this family has been split into 
three genera: Parvoviruses, Densoviruses, and Dependoviruses. Both Parvoviruses and 
Densoviruses are autonomous. Parvoviruses are typically vertebrate viruses while 
Densoviruses infect insects. AAV occupies the genus Dependovirus, a group of Parvoviruses 
dependent on a helper virus for their life cycle. Due to the general lack of pathogenicity 
displayed by AAV and other parvoviruses, discovery of new isolates and serotypes has taken 
place largely through PCR-mediated screening for related sequences.   
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The majority of AAV serotypes have been isolated from primate and human samples. 
Individual viral serotypes, by definition, can not be neutralized by sera which contains 
neutralizing antibodies to any other serotype. Because new AAV isolates are identified 
frequently and because of the challenge of cross-reacting potential new serotypes with 
antibodies against each of the others, the true number of AAV serotypes is in constant flux. 
Although AAV has been isolated from a wide range of species including snakes, birds, and 
swine, serotypes isolated from humans and primates have been explored in greater depth due 
to their potential for human gene therapy applications.  
While humans and primates harbor many closely related AAV serotypes, four 
specific serotypes have been reported to make up the majority of AAV hosted by humans. By 
testing human sera for neutralizing antibodies to different AAV serotypes, AAV serotype 2 
(AAV2) has been estimated to infect between 30-80% of the population (Table 1). AAV3 
infects approximately the same percentage. AAV5 infects substantially fewer humans, with 
only 10-20% estimated to be seropositive. AAV6 is harbored at a slightly higher rate, around 
30% (33, 40, 59, 91).  
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 Estimated % of 
Population 
Seropositive 
Tissue Tropism Rep Protein Replicates 
Vectors Flanked by:    
ITR2             ITR5    
AAV2 30-80% Kidney Yes No 
AAV3 30-80% Cochlear Inner Hair Cells Yes No 
AAV5 10-20% CNS, RPE No Yes 
AAV6 30% Skeletal Muscle Yes No 
 
      Table 1. Prevalence of Human AAV Serotypes 
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AAV serotypes 1-4 and 6 were isolated as contaminants of Ad preparations. AAV5 
was isolated from a human penile condylomatous wart (3). Most other AAV serotypes have 
been isolated from non-human tissue using PCR techniques to amplify DNA closely related 
to AAV genomic sequence. The driving force behind the search for new serotypes has been 
the promise of novel capsid variants which possess unique tropism and lead to improved 
rAAV vectors. Unfortunately, while the Rep and Cap genes can be easily isolated by PCR, 
the structure and G-C rich nature of the ITR has prevented the sequencing of these elements 
from most newly isolated serotypes. For this reason, the evolutionary relationships between 
the Rep and Cap portions of the known AAV serotypes are clearer than those of the ITR.   
Most of these serotypes display markedly different tissue tropism in vivo. AAV2, 
largely due to its utilization of heparan sulfate as a receptor, is highly efficient in transduction 
of most tissue culture cells and is the major serotype used for cell culture studies. In vivo, 
AAV2 has demonstrated the ability to transduce kidney tissue (90). AAV3 has been used to 
transduce cochlear inner ear cells, though poor transduction efficiency of tissue culture cells 
has made determination of the cell receptor a greater challenge (56). AAV5 uses alpha-2,3-
N-linked sialic acid as a receptor and has been utilized to transduce retinal cells (57). And 
AAV6, binding heparan sulfate, is able to efficiently transduce human skeletal muscle (7). 
Several non-human serotypes are also widely utilized for in vivo studies. AAV8 and AAV9 
efficiently transduce liver tissue. AAV8 also transduces the heart and pancreas. And AAV1 
is commonly used to achieve muscle transduction (100).  
Comparing the amino acid sequence of Rep and Cap, as well as the nucleotide 
sequence of the ITRs between these serotypes by phylogenetic analysis demonstrates the 
highly conserved nature of these viruses (Figure 3). All trees were generated using AAV 
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serotypes 1-9, except the ITR map due to the lack of characterized ITR sequences for several 
serotypes. The autonomous parvovirus B19 was included as an outgroup. Also included were 
the bovine, goat, and snake AAV sequences.  
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Figure 3. Phylogenetic comparison between AAV serotypes. 
Distance from tree root represents level of divergence. Trees were generated using the amino 
acid sequence of Rep or Cap of the indicated serotypes and the nucleotide sequence of the 
ITR. 
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The AAV capsid proteins are all highly conserved. AAV4 is more closely related to 
AAV5 and the other non-human/primate AAV serotypes in its Cap sequence. However, Rep4 
and ITR4 are not closely related to AAV5, suggesting a possible recombination event 
between an AAV2 and an AAV5-like serotype. Interestingly, receptor binding does not 
always correlate with serotype homology as AAV1 and AAV6 utilize different receptors 
despite extremely high homology.  
The Rep proteins are also tightly conserved. Only two of the human/primate 
serotypes, AAV8 and AAV5, deviate in any significant manner. AAV5 Rep is almost 100% 
conserved with respect to goat AAV and is also highly related to bovine AAV. AAV5 is so 
poorly conserved with respect to the other human/primate serotypes that its Rep protein 
(Rep5) is unable to function on the ITRs of those serotypes (16). Due to their high degree of 
conservation, AAV 1-4, and 6 have demonstrated complete cross-compatibility between their 
Rep proteins and ITR sequences with respect to replication (30, 31). The high degree of 
conservation of AAV7 and 9-11 suggests this inter-compatibility should also extend to them.  
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Serotype Cap Homology (aa) 
Compared to AAV2 
Rep Homology (aa) 
Compared to AAV2 
ITR Homology (nt) 
Compared to AAV2 
AAV1 83% 87% 83% 
AAV3b 87% 89% 85% 
AAV4 60% 90% 83% 
AAV5 58% 58% 49% 
AAV6 83% 87% 100% 
AAV7 82% 88% 83% 
AAV8 83% 86%  
AAV9 84% 87%  
Goat 57% 58% 49% 
Bovine 59% 58% 60% 
Snake 52% 37% 63% 
B19 22% 22% 11% 
 
      Table 2. Homology Between AAV Serotypes 
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 Thus, the phylogenetic relationships of the origin of replication between fully 
characterized human/primate AAV serotypes breaks down into two groups: The AAV5 
origin of replication and the remaining serotypes with AAV2-like origins of replication. An 
understanding of the factors which drive Rep-ITR specificity would then likely extend to all 
serotypes with the possible exception of AAV8.   
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Figure 4. Comparison between ITR2 and ITR5. 
Number of nt in each section is indicated. The Rep Binding Element (RBE) is boxed. The 
Rep Binding Element’ (RBE’) is circled. The terminal resolution site (trs) sequence is shown 
(hatched) and the nicking site is indicated by an arrow. 
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Replicative specificity between AAV2 and AAV5 does not exist at the level of 
binding, as Rep2 and Rep5 can bind interchangeably to ITR2 or ITR5 (16). Instead, 
specificity is created by the inability of Rep to cleave the ITR of the opposite serotype. This 
occurs despite high conservation between the ITR2 and ITR5 sequence, secondary structure, 
and location of elements required for Rep interaction (RBE, RBE’, trs, nicking stem; Figure 
4). 
Identification of the elements involved in Rep-ITR specificity stands to increase the 
understanding of viral and cellular DNA binding and endonucleolytic proteins. It is likely 
that similar interactions take place in a wide range of viral and cellular replication and repair 
pathways. Localization of these elements may also facilitate the identification of other unique 
Parvovirus origins of replication. Here, we demonstrate two unique mechanisms at the DNA 
and protein level to achieve Rep-ITR specificity and utilize these factors to create a novel 
AAV origin of replication. 
1D. AAV as a Gene Therapy Vector 
 Current clinical trials are using AAV to deliver genes to treat diseases such as cystic 
fibrosis, muscular dystrophy, hemophilia B, Parkinson’s, Alzheimer’s, and Canavan’s. In the 
laboratory setting, AAV is also utilized as a gene delivery tool for cell culture and in vivo 
studies. While the danger of adding exogenous DNA to cells does apply to rAAV vectors, the 
benefits of this virus with respect to other viral gene delivery methods have powered the 
rapid expansion of rAAV in the field.   
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Figure 5. AAV as a gene delivery vector. 
As the viral ITRs are the only cis-requirement for replication and encapsidation of the 
genome, the remainder of the viral genome can be replaced by exogenous sequence. A triple-
transfection of the ITR-flanked construct along with the Adenovirus helper genes required 
for Rep and Cap expression leads to production of rAAV harboring the genetic payload. 
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The ability to utilize AAV as a gene delivery vector is due to the ITRs being the only 
cis-elements required for replication and encapsidation of the genome (Figure 5). In this 
manner, any DNA sequence can be assembled into a rAAV vector by placing it between two 
ITRs. To produce rAAV, a stable plasmid carrying the vector is triple-transfected into cells 
(typically HEK 293 cells). This requires an Ad helper plasmid (pXX680) which encodes the 
four Ad proteins required for AAV replication. It also requires an AAV helper plasmid 
encoding the viral Rep and Cap genes. A wide array of AAV helper plasmids have been 
created. These allow encapsidation into the Cap of any serotype and possess the Rep 
necessary to replicate the ITRs (36, 71). Upon transfection, the Rep proteins are expressed 
and act to rescue the genome from the exogenous plasmid backbone allowing canonical 
AAV replication to occur. Forty-eight to 72 hours after transfection, the cells are harvested, 
lysed, and the resulting vector is purified through a variety of methods (28). Viral titers are 
usually measured via Southern blotting or quantitative PCR (qPCR), and transduction 
efficiency can be determined if the viral payload contains a reporter construct.  
There are a number of advantages to the use of AAV as a vector. AAV is largely non-
immunogenic in relation to other viral gene delivery methods (111). The natural tissue 
tropisms of different serotypes allow for the targeting of specific tissues, overcoming the 
concern that a vector may transduce unintended organs. This can also allow for systemic 
administration yielding transduction of tissues in a predictable manner. In addition, 
pseudotyping or using different serotypes can allow re-administration of a vector to avoid 
immune response (46).  
Another significant advantage is vector persistence. In non-dividing cells essentially 
all rAAV vector genomes circularize and persist in an episomal state, preventing the risk of 
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insertional mutagenesis (83). Vectors have been shown to persist for years in such an 
episomal state (101). Even though Rep2 has the ability to direct targeted integration of an 
ITR2-flanked genome, this is rarely a concern as Rep is not included in most rAAV vectors. 
These vectors can be delivered without concern for cytotoxic stress due to the general lack of 
pathogenicity of AAV. 
However, there are drawbacks to the use of rAAV vectors. The size of the AAV 
genome is often too small to accommodate the transgenic cassette for most therapeutic 
purposes. The vector can only be expanded to about 5.2 kb in order to achieve adequate 
vector yield (27). This limitation has led to the creation of truncated gene products, truncated 
promoters, and split vectors which exploit the natural tendency of ITR-flanked genomes to 
concatemerize (96, 104). AAV also faces the greatest challenge to gene therapy; the risk that 
the addition of exogenous DNA can lead to insertional mutagenesis. While AAV persists 
almost exclusively in an episomal state, integration into the host chromosome does occur at a 
low rate, especially in dividing cells where double strand breaks are most likely to occur (66). 
Additionally, the ITR appears to drive an increase in ectopic chromosomal integration over 
plasmid-derived therapeutic methods. Finally, the ubiquity of wt AAV in the human 
population creates the possibility of innate immunity to certain serotypes. It also leads to the 
risk that co-infection of a cell with a rAAV vector with wt AAV would allow the rAAV 
vector to be replicated and mobilized into new cells or the population at large (1, 36). 
1E. AAV Vector Mobilization  
All current AAV vectors in clinical trials utilize ITR2s. This is due to the first rAAV 
vectors being developed from AAV2. However, using ITR2s for therapeutic purposes creates 
a safety risk due to the ubiquity of AAV2 in the human population as well as AAV3 and 
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AAV6 (whose Rep proteins can replicate ITR2s),. The Rep proteins of any of these serotypes 
(AAV1-4, 6) can replicate and encapsidate an ITR2 flanked vector as they cannot 
discriminate between the ITRs of their wt genome and those of the vector. In this manner, 
rAAV vectors have the potential to be “mobilized” out of the target tissue into different 
tissues of the body or into other individuals in the population (Figure 6; 36). 
For nearly thirty years it has been known that a chromosomally integrated AAV 
genome could be rescued and replicated to allow AAV to enter the lytic phase of its life cycle 
(14). Ever since AAV was first cloned into a recombinant plasmid it has been known that the 
viral or vector genome could be rescued and replicated from exogenous DNA (77). Over ten 
years ago the first evidence for in vivo mobilization of an AAV vector transgene was 
presented, describing a potential scheme of vector mobilization between individuals (1). Yet, 
to date, only one paper has been published on preventing AAV vector mobilization (based on 
Chapter 2 of this work), and the ever increasing quantity of AAV vectors used for clinical 
trials have failed to adapt to address this concern.  
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Figure 6. Illustration of AAV Vector Mobilization. 
Administration of a rAAV vector to a cell (blue) results in delivery of the rAAV transgene 
(blue capsid and white vector) to the nucleus (orange). Co-infection by Ad and wt AAV (red 
capsid and black genome) allows AAV replication. Wt Rep proteins replicate all compatible 
ITR flanked vectors and encapsidate them into the wt capsid. These mobilized vectors could 
potentially infect new tissue within the body or other individuals. 
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There are four possible solutions to vector mobilization. The simplest method to 
decrease the risk of vector mobilization would be to use the ITRs of a serotype which is not 
as prevalent as AAV2. Rep2, Rep3, and Rep6 can all replicate the current ITR2 rAAV 
vectors (30, 31). Using ITR5 rAAV vectors would allow only wt AAV5 to mobilize the 
vector. Due to the significantly lower prevalence of AAV5 in the population, ITR5 vectors 
should be considerably safer than ITR2 vectors.  
A second method builds upon the use of ITR5s. AAV vector mobilization requires a 
cell to be infected by a rAAV vector, wt AAV, and a helper virus such as Ad. By creating a 
vector carrying one ITR2 and one ITR5, a cell would have to be infected by the vector, two 
individual AAV serotypes as well as Ad for mobilization to occur. These non-homologous 
ITR vectors have already been used to direct concatemerization of split AAV vectors (104). 
However, such vectors would need to show no replication in the presence of a single Rep 
from either serotype, and would also need to be packaged efficiently such that useful titers 
for therapeutic purposes could be achieved.  
While each of these methods would decrease the likelihood of AAV vector 
mobilization, they still use ITRs from AAV serotypes which infect the human population. In 
order to completely prevent any possibility of vector mobilization, an ITR from a non-human 
AAV serotype could be used, provided that it could not be replicated by the Rep proteins of 
any human serotype. Because AAV has been found in a large range of species, ITRs may 
exist which can not be replicated by Rep2 (or its compatible serotypes) or by Rep5. However, 
such divergent vectors may require host-specific co-factors in order to replicate, or a host-
specific helper virus. The possibility also exists that AAV may jump from these species into 
our own, nullifying any advantage from using a rAAV vector flanked by these ITRs.  
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The ideal solution to vector mobilization would be the creation of a novel Rep-ITR 
interaction. Such a vector could not be mobilized by any of the wt AAV serotypes which 
infect humans, nor the non-human serotypes which could switch to human hosts. However, 
rational design or random mutagenic approaches to create a novel AAV origin of replication 
are difficult as both the ITR and Rep would need to co-evolve to become unique from their 
wt counterparts. A novel ITR would be useless without a corresponding Rep to replicate and 
encapsidate it. Additionally, not enough is known about Rep-ITR specificity to target any 
specific portion of the protein or ITR. Due to these limitations, the first step in creating a 
novel AAV origin of replication must be to determine why replicative specificity exists 
between currently characterized AAV serotypes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Creating a Cell Culture Assay for AAV Vector Mobilization  
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2A. Introduction 
 The potential risk of AAV vector mobilization has been thoroughly characterized. 
Integrated wt AAV or rAAV genomes can be rescued from exogenous plasmid DNA, 
chromosomal DNA, and episomally persisting forms by the expression of Rep and Cap (14, 
77). Further, in vivo rAAV mobilization has been observed in primates by administration of 
wt AAV either before or after rAAV administration (1).  
The potential danger of AAV vector mobilization should make the development of a 
non-mobilizable vector a priority for those looking to take AAV vectors into the clinic. 
While potential solutions are available, such as the use of non-homologous vectors, ITRs 
from non-human AAV serotypes, or the creation of entirely novel Rep-ITR interactions, the 
first step must be the creation of mobilization assays to test such novel vectors.  
As in vivo methods would be inefficient for high-throughput screening of potential 
mobilization resistant vectors, the creation of cell culture assays to screen for mobilization is 
the best option. As two different mobilization scenarios exist, two mobilization assays must 
be created. The first is that of the presence of an AAV2 chromosomally integrated provirus 
existing prior to rAAV administration. This is due to the ability of AAV2 to integrate site-
specifically into human chromosome 19 (80). This assay would entail the co-administration 
of a rAAV vector flanked by any ITR and Ad helper into a cell line harboring an AAV2 
provirus. Assays measuring rAAV vector replication and mobilization by the wt AAV2 
genome can then be performed. However, this assay will be limited due to the lack of 
proviral cell lines for other AAV serotypes. 
A second assay must be created to account for the possibility of a co-infection of wt 
AAV and helper virus mobilizing a long-term persisting rAAV vector. In a cell culture 
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environment with dividing cells, the persisting rAAV vector would almost certainly be 
integrated into the host chromosome. A population of dividing cells harboring a persisting 
rAAV vector would approximate tissue treated with rAAV. Such cells could then be exposed 
to Rep and Cap from any serotype as well as helper virus in order to screen for mobilization 
of the rAAV vector.   
Whether the Rep-ITR specificity displayed by AAV2 and AAV5 extend to 
mobilization is unknown. It is possible that integrated AAV genomes can act as mobile 
genetic elements and recombine to excise themselves. It is also possible that Rep does not 
need to be able to replicate the ITR in order for it to catalyze excision from exogenous DNA. 
However, in order for Rep to truly mobilize a vector, it must be able to replicate and 
encapsidate the vector. Because the AAV2 and AAV5 origins of replication are exclusive 
with respect to their cognate Rep protein, AAV2 should be incapable of mobilizing an ITR5 
flanked vector, just as AAV5 should be unable to mobilize an ITR2 flanked vector (15). If 
true, the relative prevalence of these serotypes in the human population (up to 80% for 
AAV2, up to 20% for AAV5) should make ITR5 flanked vectors significantly safer (33, 40, 
59, 91). 
2B. Materials and Methods 
B1. Plasmid Construction. The Rep5 fragment was amplified from the plasmid 
AAV5-2 (gift from R.M Kotin, hereafter referred to as pRep5Cap5) via polymerase chain 
reaction (PCR) using the forward primer rep-5 F1 5’-
CGAGCTCGGCGCGTATGAGTTCTCGC-3’ and the reverse primer rep-5 R1 5’-
GACTACTCGCTTTATTTACTGTTC-3’, which added an upstream SacI restriction site. 
The Cap2 fragment was amplified from the plasmid pXR2 (71) using forward primer 5’-
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ATGGCTGCCGATGGTTATCTTC-3’ and reverse primer 5’-
TGGTGATGACTCTGTCGCCC-3’, which included a NotI restriction site downstream from 
Cap2.  The Rep5 and Cap2 fragments were ligated back into the pXR2 plasmid via the SacI 
and NotI restriction sites, in a triple-fragment ligation, to make pRep5Cap2.  The pRep5Cap2 
plasmid was used as a template for construction of the remaining plasmids.  The pXR 
plasmid series contain Rep2 or chimeric replication genes with the cap genes from AAV 
serotypes that correspond to the plasmid number (71).  The forward primers were pxr1/3 F 
(5’-ATGGCTCGGCATCCTTATCTTC-3’) and pxr4F (5’- ATGGCTGCTGACGGTTACC-
3’), and the reverse primers were pxr1/3 R (5’- CTATGACCATGATTACGCCAAGC-3’) 
and pxr4 R (5’-CAGCTATGACCATGATTACGC-3’). The amplified region included a NotI 
restriction site downstream from the capsid genes. The Rep5 and Cap fragments were ligated 
into the pRep5Cap2 backbone via PpuMI and NotI restriction sites. Rep5Cap1-4 plasmids 
were confirmed by restriction site analysis and DNA sequencing.  Vector plasmids included 
the transgene eGFP preceded by the CMV promoter and followed by the SV40 
polyadenylation (p(A)) signal, flanked by AAV type 2 ITR (TR2-eGFP) or AAV type 5 ITR 
(TR5-eGFP) (Figure 7A).  A neomycin cassette lies downstream driven by a TK promoter 
and the bovine growth hormone p(A) signal.  Note that the ITR5-eGFP plasmid has an 
additional 500 bp insert upstream of the 3’ ITR in order to distinguish it from ITR2-eGFP on 
a gel. The pRep6Cap6 plasmid was obtained from David Russell (75).  
B2. Cell culture. HEK 293 and Cos1 cell lines were originally obtained from the 
American Type Culture Collection (ATCC) (Rockville, Md.).  Detroit 5 (D5) and Detroit 6 
(D6) human bone marrow cells were a gift from K. Berns.  The D5 cell line was originally 
cultured as a clone of wt AAV2 latently-infected D6 cells (14) and contained wt AAV2 DNA 
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integrated into the chromosomal DNA.  All cells were maintained at 37oC with 5% CO2 
saturation in media supplemented with 10% fetal bovine serum (Sigma) and 20 units/ml 
penicillin/streptomycin. HEK 293, Cos1, D5 and D6 cells were cultured in Dulbecco 
modified Eagle medium, while CHO pgsD-677 cells were grown in Ham F12 medium.  CHO 
pgsD-677 cells were also obtained from the ATCC (89).   
B3. Production of rAAV. Approximately 2x107 HEK 293 cells were triple-
transfected with 10 µg AAV helper plasmid (encoding Rep2 or Rep5 and Cap2), 10 µg 
pXX680 (Ad helper plasmid), and 10 µg either ITR5-eGFP or ITR2-eGFP plasmid transgene 
vector.  These constructs were mixed with 500µl DMSO and 100µl PEI prior to 5 min 
incubation at 25oC and dropwise addition to HEK 293 cells.  At 48 hours post-transfection, 
cells were harvested for collection of cell lysate, Hirt DNA, and protein.  Virus particles were 
collected from cell lysates produced from triple freezing and thawing of cells and 
centrifugation to remove cell debris.  
B4. Hirt DNA Purification and Southern Blot Analysis. Hirt DNA purification was 
performed as described (41). Briefly, cells were harvested 48-72 hours post-transfection and 
washed in Phosphate Buffered Saline (PBS) and resuspended in 370ul Hirt Solution (0.01M 
Tris-HCl pH 7.5 and 0.1M EDTA) prior to addition of 25ul 10% SDS and 165ul 5M NaCl. 
Samples were then stored at 4oC overnight prior to centrifugation. Supernatant was purified 
by the addition of UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1) (Invitrogen) and 
DNA was precipitated and isolated by the addition of an equal volume of isopropanol. 
Samples were resuspended in 50ul sterile ddH2O. 5ul of each sample was digested with 4U 
DpnI (NEB) 2-4 hours at 37oC prior to gel electrophoresis and Southern blot analysis as 
described (19). The nylon membrane (Hybond-XL) (GE Healthcare Life Sciences) was 
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hybridized to a probe corresponding to the GFP open reading frame labeled with the Random 
Primed DNA Labeling Kit (Roche) and d-CTP P32. Blots were visualized after exposure to a 
phosphorimager screen (GE Healthcare Life Sciences).  
B5. In Vitro Transduction Assay. Lysate from each transfection was tested for 
infectivity to ascertain virus production.  1 x 105 HEK 293 or Cos1 cells were seeded in each 
well of 48 well plates.  Cos1 and CHO pgsD cells were used to assay AAV4 and AAV6 
respectively since they transduce HEK 293 cells at a low efficiency. Original cell lysates 
harvested from transfections were diluted to a range from 1x 10-1 to 1 x 10-8.  100 µl of each 
serial dilution in addition to Ad (m.o.i. of 5) were added to cells.  Each infection was done in 
duplicate.  At 24 hours post-infection GFP positive cells were visualized.  Under 200x 
magnification, the number of GFP positive cells per field was counted.  Ten fields per well 
were counted and the average number of GFP positive cells/field was determined.  This 
number was multiplied by the number of fields per well and divided by the amount of lysate 
added to each well (as given by the dilution factor) to determine the number of transducing 
units (TU) per µl of cell lysate.  
B6. Quantitative PCR for Virus Titer. Virus particles/µl was determined for each 
virus preparation.  10 µl of partially-purified cell lysate (see “Production of rAAV” in 
Methods) was added to 90 µl DNaseI Solution (10 µg DNaseI, 10 mM tris pH 7.5, 10 mM 
MgCl2, 2 mM CaCl2) and incubated for 1 hour at 37oC and stopped with the addition of 6 µl 
0.5M EDTA.  Then 120 µl of Proteinase K solution (1M NaCl, 1% Sarkosyl, 20 µg 
Proteinase K) was added and each sample was incubated for 2 hours at 55oC.  Each sample 
was heated at 95oC for 10 minutes, diluted 1:500 or 1:5000, and used directly as template for 
qPCR.  
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 For quantitiation of DNase-resistant viral genomes in the sample, 2 µl were used as 
template in a 10 µl real-time PCR reaction.  The LightCycler FastStart DNA master SYBR 
Green I kit (Roche # 12239264001) was used following the manufacturer’s instructions, 
using 3 mM MgCl2 and 500 nM of each primer. All reactions were carried out on a Roche 
diagnostic real-time PCR LightCycler 2.0. For each reaction, the cycling parameters were as 
follows:  10 minutes at 95°; 5 cycles at 95° for 15 sec, 64° for 5 sec, and 72° for 15 sec; 5 
cycles at 95° for 15 sec, 62° for 5 sec, and 72° for 15 sec; 40 cycles at 95° for 15 sec, 60° for 
5 sec, and 72° for 15 sec.  At the end of each run, a melting curve analysis was performed in 
which the PCR products were annealed at 72° and the temperature was gradually raised to 
99°. In all cases, the PCR products melted in a narrow temperature range, indicating a pure 
PCR product without detectable non-specific amplification.  The following primers were 
used:  QGFP1-F 5’-AGCAGCACGACTTCTTCAACTCC-3’ and QGFP1-R 5’-
TGTAGTTGTACTCCAGCTTGTGCC-3’.  A plasmid containing GFP, pTR2-GFP, was 
used to generate the standard curve.  
B6. Dot Blot for Virus Titer. Dot blots were performed using 10µl per sample of 
purified cell lysate used in the various transduction assays, as described (21).  The samples 
were blotted to a nylon membrane using a dot blot manifold and UV crosslinked at 
60mJoules (UV Stratalinker 1800, Stratagene). The Southern blot was hybridized to a 
radiolabeled GFP probe (see “Hirt DNA Analysis” above) and exposed to film or visualized 
using a Storm Phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA).   
B7. DNA Alignment and Generation of Phylogenetic Trees. ClustalW2 was used 
for all DNA alignments and to generate phylogenetic trees (49). The amino terminal 200 
amino acids of the large Rep proteins from AAV serotypes 1-12 were used to generate a 
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phylogenetic tree by the PHYLIP method. This program also calculated the percent 
homology between the Rep proteins of different serotypes.  
B8. Mobilization of ITR2 and ITR5 Vector Genomes by an AAV2 Provirus. D6 
and D5 cell lines were infected under four different conditions.  A 10 cm plate of each cell 
line approximately 75% confluent was incubated overnight at 37oC in 5% CO2 saturation 
with 50µl AAV2 ITR2-eGFP or AAV2 ITR5-eGFP cell lysate.  Cells were then washed four 
times with 10 ml DMEM and co-infected with Ad (m.o.i. of 10). Control plates were infected 
with only AAV2 ITR2-eGFP or only Ad.  At 96 hours post-infection cell lysate and Hirt 
DNA from each infection were harvested as described above.  Hirt DNA was separated by 
electrophoresis on a 0.8% agarose gel and transferred to a nylon membrane.  The blot was 
probed for GFP as described above.   The membrane was stripped by boiling with 1% SDS.  
The membrane was re-hybridized with a probe specific for Rep2 and Cap2.  Additionally, 
cell lysates from each infection and Ad (m.o.i. 5) were used to infect 1 x 105 fresh HEK 293 
cells.  Cells positive for GFP were visualized 24 hours post-infection. 
B9. Creation and Mobilization of AAV Vector Genomes from Stable GFP 
Expressing Cell Lines. 1 x 105 HEK 293 cells were infected with 10,000 vector 
genomes/cell of ITR2- or ITR5-eGFP rAAV and were then cultured for 18 days. Cells 
(approximately 1% GFP positive) were then trypsinized and subjected to flow sorting with a 
Beckman-Coulter Dako Moflo to isolate GFP positive cells. 1500 GFP positive cells were 
pooled into one well of a 96-well plate and allowed to propagate. GFP expression was 
monitored to insure a homogeneous GFP positive population in which the transgene was 
maintained. AAV helper plasmids were transfected into these cells in 10-cm dishes and 
incubated for 48 hours prior to Hirt DNA extraction and preparation of crude lysate. 
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2C. Results 
C1. The AAV5 Origin of Replication is Unique Among Human Serotypes. As 
previously reported, Rep1-4 and 6 are unable to catalyze replication of ITR5 flanked 
genomes, while Rep5 is unable to catalyze the replication with vectors flanked by ITR1-4, 
and 6 (30, 31). Due to high sequence homology, it is likely that AAV serotypes 7-12 are also 
compatible with ITR2s and not ITR5s (Figure 3 and Table 1). In order to demonstrate the 
specificity of the Rep5-ITR5 interaction, two GFP vectors were utilized (Figure 7A). These 
constructs, ITR2-eGFP and ITR5-eGFP, are flanked by either ITR2s or ITR5s and expressing 
GFP from a CMV promoter. The rAAV vectors were transfected into 293 cells along with 
Ad helper plasmid (pXX680), and either Rep2Cap2, Rep5Cap2, or Rep6Cap6. Rep6 was 
included to confirm the cross-compatibility of AAV2 and AAV6 replication, as well as to 
underscore the ability of other naturally occurring serotypes to replicate ITR2 vectors. After 
48 hours, cells were harvested for Hirt DNA and crude lysate. Hirt DNA (41) was analyzed 
by Southern blot with a probe for the GFP orf. A DpnI digestion was performed to remove 
transfected methylated plasmid DNA, but not unmethylated genomes which had been 
replicated in the cell.  The results validated Rep-ITR specificity for the serotypes used, with 
Rep2 and Rep6 driving replication of only ITR2 vectors, and Rep5 driving replication of 
only the ITR5 vector. (Figure 7B). Crude lysate from these cells was used to transduce HEK 
293 cells (highly transducible by Cap2) and CHO pgsD cells (transducible by Cap6) (Figure 
7C). Specificity in the production of rAAV vectors followed the same pattern as replication, 
with Rep2 and Rep6 each able to produce infectious ITR2 rAAV particles and Rep5 able to 
produce only infectious ITR5 rAAV particles.  
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Figure 7. The Rep5-ITR5 interaction is unique among the fully characterized AAV 
serotypes. 
(A) The vector constructs used in this study. GFP expression was driven by a CMV promoter 
and SV40 poly(A) element. The Neomycin cassette included the thymidine kinase promoter 
and the bovine growth hormone poly(A) element. TR2s or TR5s flanked the vectors. pTR5-
eGFP contained an additional 500bp ahead of the 3’ TR.  
(B) Southern blot of Hirt DNA comparing the ability of Rep2Cap2, Rep5Cap2 and 
Rep6Cap6 to replicate TR2s or TR5 flanked vector genomes. Hirt DNA was isolated 48 
hours after transfection. DpnI cuts only the input plasmid, not the newly replicated AAV 
genomes. The two major replicative forms of AAV are indicated (m-double stranded 
monomer, d-double stranded dimer). Higher-order replicative forms are also visible.  
(C) Transduction of HEK 293 cells (transducible by Cap2) or CHO pgsD cells (transducible 
by Cap6 or Cap2) with crude lysate from cells harvested 48 hours after transfection of Ad-
helper plasmid only or triple-transfection of Ad-helper plasmid, TR2 or TR5 GFP, and either 
Rep2Cap2, Rep5Cap2, or Rep6Cap6. The numbers shown correspond to the lane of the gel 
in figure 2B. 
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C2. Creation and Characterization of Rep5 Helper Constructs for Cap1-5. As 
the prevalence of AAV5 in the human population is lower than AAV2 or AAV6, and 
considering the unique specificity between Rep5 and ITR5, we decided to create a rAAV 
ITR5 production system for transcapsidation into Cap1-5 similar to previous described 
system for type 2 (71). In order to confirm the efficacy of ITR5 vectors with respect to 
existing ITR2 vectors, Rep5 helper constructs were created (Figure 8A).  This new system 
for producing virus vectors utilizes triple transfection with AAV helper plasmids containing 
the AAV5 Rep gene and one of the AAV serotype 1-5 Cap genes (pRep5Cap1-5), a reporter 
transgene plasmid with GFP flanked by AAV5 ITRs, and an Ad helper plasmid (XX680). 
HEK 293 cells were transfected with pRep5Cap1-5, Ad helper plasmid, and ITR2 or ITR5 
eGFP.  Analyses of Hirt DNA extracted from these cells showed that Rep5 functioned 
properly, generating the expected DpnI-resistant AAV monomer and dimer replication 
intermediates when delivered with the ITR5-eGFP but not the ITR2-eGFP vector (Figure 8B).  
Additionally, cell lysate harvested from each transfection was tested for infectivity to 
ascertain the system’s ability to produce functional recombinant virus.  HEK 293 or Cos1 
cells were exposed to lysate from the ITR5 transfections and assayed for GFP expression at 
24 hours post-infection.  Lysate carrying capsid-specific sequences (types 1-5) all produced 
GFP-positive cells when ITR5 was complemented with Rep5 expression plasmids during 
vector production  (Figure 8C, panels 1-5).  Cells exposed to lysate from ITR2 transfections 
in the presence of Rep5 proteins were negative for transgene expression (Figure 3C, panel 6).   
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Figure 8. Creation and characterization of Rep5 helper constructs for Cap1-5. 
(A) The AAV5 Rep and AAV1-4 Cap genes were subcloned into pXR2, a non-ITR-
containing plasmid (see Methods for details).  These new helper plasmids were used to 
package TR5 vectors into Cap1-5.  
(B) Southern blot using a GFP specific probe of Hirt DNA extracted from HEK 293 cells 
transfected with pRep5Cap1-5, Ad helper plasmid, and TR5-GFP or TR2-GFP. The two 
replicative forms of the vector are indicated.  
(C) Cell lysate from triple transfections described above were used to infect naïve HEK 293 
cells.  Cells infected with lysate from TR5-eGFP vector transfection of capsid serotypes 1-5 
were positive for GFP (panels 1-5 corresponding to AAV1-5).  HEK 293 cells infected with 
lysate from TR2-eGFP vector transfection of capsid serotypes 1-5 did not express GFP 
(panel 6, AAV1; representative of AAV2-5).  
(D) Graph comparing the relative titers achieved in the production of TR2 vs. TR5 rAAV. 
Samples were titered in duplicate by Q-PCR. Standard error is indicated.  
(E) Graph comparing the transducing units per vector genome of rAAV TR2 vs. TR5 vectors. 
Note that values on the y-axis are multiplied by 1x10-7.  Virus was serially diluted and used 
to infect cells. GFP positive cells were quantitated and transducing units per microliter was 
calculated before conversion to transducing units per vector genome. Samples were measured 
in duplicate and standard error is indicated. 
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Having developed a functional AAV capsid production system using ITR5s, we 
sought to compare it to current Rep2-ITR2 production yields.  The protocol designed by our 
lab (71) for production of transcapsidated rAAV2 (i.e., using helper plasmids that contain 
AAV Rep2 and serotypes 1-5 capsid genes, a reporter transgene (GFP) in an ITR2 vector 
cassette, and Ad helper plasmid) was used as a comparison to evaluate the new Rep5-ITR5 
system. Cell lysate was harvested from each transfection and assayed for virus production by 
Q-PCR titering to determine virus particle number per unit volume of lysate (Figure 8D).  
The measurements obtained from the dot blots are comparable for ITR2 and ITR5 vectors 
when packaged in AAV serotype 1-4 capsids.  Interestingly, ITR2 vector titers were 
noticeably reduced when packaged in an AAV5 capsid, possibly due to the evolutionary 
divergence of AAV5 with respect to the other serotypes (Figure 3 and Table 1).  Both ITR5 
and ITR2 vector production systems were also assayed for infectivity as measured by the 
number of transducing viral units per vector genome (Figure 8E).  1 x 105 HEK 293 cells 
were exposed to serial dilutions of cell lysate from each transfection, and the number of 
resulting transgene-positive cells was used to calculate the transducing units per microliter 
(TU/µl) of cell lysate.  This was then divided by the viral titer (vg/ul) to yield the transducing 
units per vector genome (TU/vg).  ITR5 vectors displayed a minor drop in transduction 
efficiency compared to ITR2 vectors, ranging from 5-10 fold in Cap1-3, while ITR5 vectors 
performed better in Cap5. This data demonstrates the transduction potential of each 
individual vector genome, again suggesting that due to evolutionary divergence, ITR5 
vectors may have slightly better transduction potential when encapsidated in an AAV5 capsid. 
Transduction of the HEK 293 cells by Cap4 was below the detection threshold of the assay.  
The results indicate that while the yields of ITR5 rAAV vector production is equivalent to 
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the widely utilized ITR2 system, there may be a capsid specific effect on the ability of these 
vectors to transduce cells efficiently. 
C3. ITR2 but not ITR5 Vectors can be Mobilized by a wt AAV2 Provirus. AAV2 
has been consistently demonstrated to be the most prevalent natural AAV serotype in the 
human population (33, 40, 59, 91); thus there is a strong likelihood that a large percentage of 
human individuals harbor a latent AAV2 infection (65). For that reason, we obtained Detroit 
5 (D5) cells demonstrated to contain a latent wt AAV2 infection in order to model the 
potential for ITR2 or ITR5 vector mobilization upon rAAV and Ad infection.  The D5 cell 
line contains the wt AAV2 genome which is stably integrated at chromosome 19 and is 
rescuable upon infection by helper virus (14, 80). The parental line, Detroit 6 (D6), is 
negative for wt AAV and was used as a control.  Cell lysate containing ITR2 or ITR5-
flanked rAAV GFP genomes encapsidated into Cap2 were harvested from triple-plasmid 
transfections of HEK 293 cells.  Each type of lysate was used to infect D5 and D6 cells.   
After 24 hour incubation, cells were washed and co-infected with Ad helper virus.  Control 
plates were exposed to lysate containing either AAV2 ITR2-eGFP only or Ad only.  
Transgene GFP expression was observed in all cells receiving the original cell lysate, 
confirming the infectivity of AAV2 ITR2-eGFP and AAV2 ITR5-eGFP in D5 and D6 cells 
(data not shown).  Hirt DNA analysis from infected cells revealed rescue of latent AAV2 
genes, in the form of AAV2 replication intermediates, in D5 cells infected with Ad (Figure 
9A).  As expected, D6 cells without latent AAV or D5 cells without Ad did not show AAV2 
replication intermediates (Figure 9A).  In addition, rescued latent wt AAV2 genomes were 
able to complement rAAV vector genomes when assayed by Southern blot analysis.  For 
example, replication intermediates were observed in D5 cells exposed to the ITR2 vector 
 44 
while no vector replication was observed in the cells exposed to the ITR5 vector. (Figure 9B).  
Longer exposure revealed minor ITR5 vector signal in D5 cells, comparable to background 
levels of ITR5 and ITR2 vector signal found in D6 Hirt DNA, indicating a lack of replication 
in the presence of Ad.  
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Figure 9. TR2 but not TR5 vectors are mobilized by latent wt AAV2 and Ad coinfection. 
Detroit 6 (D6, Latent AAV2 (-)) or Detroit 5 (D5, latent AAV2 (+)) cell lines were infected 
with rAAV2 from crude lysate containing TR2 or TR5-eGFP in the presence or absence of 
adenovirus.  Hirt DNA was isolated and analyzed by Southern blot 48 hours post-infection 
using either an AAV2 (A) or GFP (B) probe.  The two major replicated forms of AAV DNA 
are indicated.  Larger replicative forms are also visible. Size marker is denoted. (C) GFP 
expression was visualized in HEK 293 cells after crude lysate was added from either D5 or 
D6 cells infected with the vectors shown above the panels. The numbers refer to the gel lane 
in figure 5B. 
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Lysate taken from ITR2 or ITR5 eGFP vector-infected D5 and D6 cells was used to 
infect naïve HEK 293 cells (Figure 9C).  HEK 293 cells given lysate taken from D5 cells 
exposed to the AAV2/TR2-eGFP vector and Ad were positive for GFP (Figure 9C, panel 6), 
demonstrating that latent wt AAV2 was able to provide Rep and Cap in trans to mobilize the 
ITR2-flanked GFP vector.  In contrast, HEK 293 cells given lysate from D5 cells infected 
with the ITR5-eGFP vector did not express GFP (Figure 9C, panel 7), demonstrating that the 
latent AAV2 was not able to mobilize the ITR5-flanked GFP vector.  As expected, control 
lysate from D6 cells did not produce infectious GFP vectors using either ITR, and infection 
of D5 cells without Ad helper or without ITR2-eGFP vector did not produce infectious GFP 
vectors (Figure 9C, panels 1-5).   
C4. Persisting AAV Vector Genomes can be Mobilized. During infection, AAV 
genomes not degraded have two fates: episomal formation or chromosomal integration (17, 
63). While wt AAV2 has been shown in tissue culture cells to integrate into the human 
chromosome in a site specific fashion (14, 80), it has been demonstrated that Rep is required 
for this form of latency (4).  Ideally, rAAV vectors should be delivered in the absence of Rep, 
wherein numerous studies have determined that rAAV genomes remain episomal, typically 
circularizing or forming into concatemers as a mechanism of vector persistence. (18, 83, 102) 
Thus, the infrequent event of integration by rAAV genomes is not site specific (63).  
Regardless of the method of molecular persistence, AAV genomes are able to excise 
themselves from the chromosome or episome upon Ad superinfection to enter the lytic phase 
of the AAV lifecycle, suggesting wt AAV persists in a conservative manner, keeping at least 
one ITR sequence intact. (80)   
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To test whether persisting rAAV vectors could be rescued after infection in the absence 
of site-specific integration, we infected HEK 293 cells with 10,000 vector genomes/cell of 
either ITR2 or ITR5 GFP virus as determined by dot blot. After 18 days, GFP cells were 
sorted and pooled to approximate a population of cells infected by the vector. While we did 
not confirm these vectors had integrated into the host chromosome, we did confirm that after 
sorting, GFP persistence remained in 100% of the cells for greater than two months. 
Rep2Cap2, Rep5Cap2, or Rep6Cap6 as well as Ad helper plasmid were transfected into the 
mock, ITR2, or ITR5 containing cell lines and both Hirt DNA and crude lysate were isolated. 
Figure 10A reveals both ITR2 and ITR5 genomes were capable of being rescued and 
replicated (lanes 6, 8, 11). Specificity remained consistent for these vectors, with both Rep2 
and Rep6 able to rescue and replicate ITR2s and only Rep5 able to replicate ITR5s. The 
pTR5-eGFP panel was exposed longer than the ITR2 or mock due to the small amount of 
replicated vector DNA isolated from these cells.  
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Figure 10. AAV genomes conferring long-term transgene expression in cultured cells 
can be rescued, replicated, and packaged. 
 (A) 293 cells were infected with either ITR2 or ITR5 eGFP vectors and passaged 18 days 
before cells still expressing GFP were sorted and pooled. AAV helper plasmids (Rep2Cap2, 
Rep5Cap2, Rep6Cap6) were then added to assay for the ability of persistent AAV genomes 
to be rescued and undergo replication in the presence or absence of Ad helper plasmid. Hirt 
DNA was isolated and assayed via Southern blot with a probe for the GFP ORF. The two 
major replicative forms of the vector genomes are indicated. Larger replicative forms are also 
visible. The TR5 (+) helper plasmid panel of the blot was subjected to longer exposure in 
order to visualize the replicating vector genomes.  
(B) Mobilized genomes were assayed for infectivity by transducing HEK 293 or CHO pgsD 
cells with crude lysate from the cells described in figure 10A (control, TR2, or TR5 
persisting vector genomes transfected with the helper plasmids described) 48 hours after 
addition of helper plasmids (All transfections for lysate used in figure 10B included Ad 
helper plasmid).  
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To determine if these rescued, replicating genomes could be encapsidated and mobilized 
to naïve cells, lysate was added to HEK 293 or CHO pgsD cells. Figure 10B shows that 
rescued genomes were encapsidated and that persisting rAAV genomes can be mobilized into 
previously non-transduced cells (HEK 293 panels 6 and 11 and CHO pgsD panel 8). 
Predictably, the transduction profile of the mobilized ITR2 or ITR5 vector genomes was 
dependent on the capsid into which they were packaged (Cap2 or Cap6), highlighting the 
potential danger of ITR2 vector mobilization being driven by a range of wt AAV serotypes.    
2D. Discussion 
This aim suggests that AAV5 based vectors are significantly less likely to be 
mobilized after administration than the AAV2 based vectors currently used in clinical trials. 
The two most prevalent human AAV serotypes (AAV2 and AAV6) both have the ability to 
replicate the ITR2 flanked vectors currently used in AAV clinical trials (30). A less 
widespread AAV serotype, AAV5, has a unique Rep-ITR interaction making it the only 
human serotype able to replicate ITR5 flanked vectors (16, 30, 52). This replicative 
specificity, as well as the relative abundance of these serotypes in the population, (AAV5 
over four-fold less abundant that AAV2 (33, 40, 59, 91) led us to hypothesize that ITR5 
flanked vector genomes have a significantly reduced risk of vector mobilization.  
To test this hypothesis, we created an ITR5 based vector production system similar to 
the ITR2 based system currently used to produce rAAV (Figure 8A). This system worked 
well, exclusively packaging ITR5 flanked vectors into Cap1-5 while yielding comparable 
viral titers and transduction efficiency with respect to the current ITR2 vector production 
system. While our ITR5 vectors may have shown a minor inherent decrease in transduction 
efficiency (potentially in a capsid specific manner) optimization of our system may eliminate 
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this disparity. A similar comparison between ITR2 and ITR5 vectors in vivo showed no such 
bias, (30) suggesting the differential may be due to the sensitivity of our in vitro system or 
otherwise restricted to our assay.  
In order to confirm that Rep-ITR replicative specificity extended to vector 
mobilization we adopted two cell culture assays. While the transformed cells used for these 
assays had the potential to behave differently from the primary cell types AAV vectors would 
encounter in vivo, we reasoned that Rep-ITR specificity would remain consistent regardless 
of cell type. That said, demonstrating vector mobilization in primary cells remains an 
important step in establishing the potential danger to future gene therapy candidates.  
First, we showed that in cells with latent wt AAV2 infection, introduction of an ITR2 
vector and subsequent superinfection by Ad resulted in replication of the wt genome and the 
ITR2-flanked transgene, (Figure 9A and 9B) and led to the production of infectious rAAV 
particles (Figure 9C).  These results demonstrated that latent wt AAV2 plus Ad reconstituted 
the replication-deficient ITR2 vector system, allowing for mobilization of transgene vectors. 
Once again, AAV2 was unable to replicate or mobilize an ITR5 flanked genome (Figure 9B, 
lane 7), underlining the potential of our ITR5 based system to decrease AAV vector 
mobilization due to relative AAV2, AAV5, and AAV6 prevalence in the population. While 
inclusion of a cell line harboring a latent AAV5 genome would have been ideal for this study, 
there are no reports of AAV5 integrating site-specifically into the human chromosome. Thus, 
any cell line harboring an AA5 genome should be recapitulated by our mobilization system 
in figure 4 where a persisting ITR5 flanked genome is rescued and replicated.  
Next, cell lines were first created containing stably persisting ITR2 or ITR5 flanked 
vector genomes. While we did not determine whether these genomes were integrated into the 
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host chromosome, the persistence of GFP signal in 100% of these cells two months after 
sorting suggests chromosomal integration. However, the possibility that they are persisting in 
some other manner only lends credence to the mobilization assay we have developed, as such 
genomes may recapitulate any number of modes of persistence in vivo. We next 
demonstrated that these persisting rAAV genomes could be rescued and replicated upon the 
transfection of AAV helper plasmids (Figure 10A).  These genomes were also encapsidated 
and able to transduce naïve cells (Figure 10B).  Predictably, the cell/tissue tropism of these 
mobilized genomes was dependent on the capsid into which they were mobilized. 
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Figure 11. AAV Vector Mobilization Assay. 
Cells infected with a rAAV GFP reporter flanked by the ITR of any serotype are passaged for 
18-20 days, typically resulting in 1-4% of cells GFP positive (1). GFP positive cells are 
sorted and pooled (2). Cells are infected or transfected with Ad and any AAV serotype in 
order to mobilize genomes (3). Mobilization is determined by Southern blot of replicating 
genomes as well as infection of naïve cells with lysate.   
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Slightly different levels of replication were detected for pTR2-eGFP vectors in the 
presence of Rep2 or Rep6. (Figure 7B and 10A). While this may suggest Rep6 replicates 
ITR2s with higher fidelity than Rep2, it is more likely that more Rep6 protein was produced 
by the plasmid constructs. Western blots were not performed due to the lack of a suitable 
Rep6 antibody. Interestingly, our ITR5 vector was rescued with lower fidelity from 293 cells 
than our ITR2 vector (Figure 10A). We have confirmed that our Rep2 and Rep5 constructs 
produce equivalent amounts of protein by western blot (data not shown) and that they drive 
comparable amounts of vector genome replication (Figure 7B). As such, the decreased rescue 
of ITR5 genomes is most likely due to the inability of a subset of the ITR5-flanked GFP 
vectors in this population to be rescued due to deletions of the integrated or concatamerized 
ITRs as seen with AAV 2 latent genomes (106). It is possible, however, that persisting ITR5 
genomes may be somewhat refractory to rescue and further experiments may be required to 
definitively answer this question.  
It is impossible to quantify the degree of safety ITR5 based vectors would add to 
AAV clinical applications. Based on the exclusivity of the Rep5-ITR5 interaction, as well as 
the small degree of AAV5 in the population compared to AAV2 and AAV6, we can only 
postulate that ITR5 vectors possess a significantly lower risk of spreading after rAAV 
administration. While ITR5 based vectors may be markedly safer, they are not a solution.  
More importantly, this work provides an assay to test the ability of any AAV vector 
to be mobilized by any wt AAV serotype. While the ability to test for mobilization of a 
vector by an AAV2 provirus is critical, such an approach would require the creation of new 
cell lines containing a provirus of every AAV serotype so that each ITR vector could be 
screened for mobilization. Instead, the ability to infect with a vector harboring any ITR and 
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then mobilize with the Rep and Cap of any serotype will allow efficient screening of any 
novel or non-human ITR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Mapping Protein/DNA Specificity of the AAV Origin of Replication 
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3A. Introduction 
Having developed assays to screen vectors for mobilization against an AAV2 
provirus as well as to screen any vector against mobilization by any AAV serotype, the next 
step towards preventing vector mobilization was the creation of a novel Rep-ITR interaction. 
To do so, however, required an understanding of the elements of the AAV origin of 
replication that govern replicative specificity. Identifying these elements was necessary to aid 
the rational design that would be required to engineer a new and unique Rep-ITR interaction.  
Initial mapping of the Rep protein has revealed that only the unique N-terminus of the 
large Rep proteins possesses the ability to bind site-specifically and to nick the ITR, 
specifically the N-terminal 208aa (107). As such, chimeric Rep proteins have been created 
which carry the N-terminal 200 residues of one serotype and the C-terminus of the other. 
These chimeric Reps specifically replicate the ITR corresponding to its N-terminus (107).  
Previously, AAV replicative specificity was postulated to be driven by the trs 
sequence (16). Rep2 can nick the ITR2 trs (AGT/TGG) and the AAVS1 trs of human 
chromosome 19 (GGT/TGG; 98). Rep5 nicks only the ITR5 trs (AGTG/TGG). However, 
alignment of the ITR2 and ITR5 sequences revealed several significant sequence and 
structural differences outside the trs sequence (Figure 4). The spacing between the putative 
RBE and the nicking stem was significantly different; three nt for ITR2 and 15 nt for ITR5. 
Additionally, while the trs sequence is not tightly conserved between ITR2 and ITR5, neither 
is the height or overall length of the putative nicking stem. 
In order to address these concerns the ITR was synthesized and amplified in halves 
(Figure 12). Assembly of the halves required the inclusion of a SfiI site in one of the hairpin 
arms of the ITR. SfiI allowed the conservation of the RBE’ sequence (10). Cloning the ITR in 
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a DD format required only one ITR per plasmid for replication (103). The three core Rep 
functions necessary for AAV replication (Rep binding, helicase, and nicking) were analyzed 
by the presence or absence of intracellular replication of the plasmid. This assay provided the 
ability to quantitate Rep-ITR function in a physiological setting, removing the concern that 
highly purified Rep protein might take on aberrant function in vitro. This system also 
avoided concerns that previous in vitro assays used only a fragment of the ITR or that oligos 
used to recapitulate the ITR might not fold correctly. 
Identification of the elements involved in Rep-ITR specificity stands to increase the 
understanding of viral and cellular DNA binding and endonucleolytic proteins. It is likely 
that similar interactions take place in a wide range of viral and cellular replication and repair 
pathways. Localization of these elements may also facilitate the identification of other unique 
Parvovirus origins of replication. Here, we demonstrate two unique mechanisms at the DNA 
and protein level to achieve Rep-ITR specificity and utilize these factors to create a novel 
AAV origin of replication. 
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Figure 12. Diagram of ITR synthesis. 
 (A) The ITR was synthesized as oligonucleotides in two pieces (dark blue and light blue) 
overlapping across one hairpin stem containing the SfiI site (orange).  
(B) Each half was amplified via PCR prior to digestion and cloning. 
(C) Proper triple-ligation with pUC18-CMV GFP produced an ITR in DD format.  
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3B. Materials and Methods 
B1. ITR Cloning. ITRs were cloned into a pUC-18 plasmid with a GFP cassette 
(CMV promoter, SV40 polyA) cloned between the KpnI and EcoRI restriction sites. The 
ITRs were synthesized in two halves as 4nmol Ultramer DNA oligos (Integrated DNA 
Technologies). SfiI restriction sites were incorporated into one hairpin arm the ITR for 
cloning (Figure 12). Due to inconsistencies of the reported sequence at the tip of the ITR5 
hairpins between Chiorini et al., 1999, the published genbank sequence (genbank accession 
number NC_006152), and restriction mapping (data not shown), an ITR2 hairpin was utilized 
for the ITR5 construct (Figure 12). 200pg of each oligo was amplified in a PCR reaction 
using the ITR primers listed in supplemental table 1. 2.5U of PfuTurbo DNA Polymerase 
(Stratagene) was used to amplify each half of the ITR as follows: 1 cycle at 94oC for 4 
minutes, 35 cycles of 45 seconds at 94oC, 30 seconds at 50oC, and 30 seconds at 72oC, 1 
cycle of 10 minutes at 72oC. PCR reactions were purified and subject to digestion by KpnI 
and SfiI or HindIII and SfiI (NEB). A triple ligation with the pUC-18 GFP plasmid and each 
half of the ITR was performed with T4 DNA Ligase (Invitrogen) for 1.5 hours at room 
temperature. All constructs were verified by DNA sequencing at the UNC-CH Genome 
Analysis Facility after linearization of the plasmid and ablation of the ITR secondary 
structure by SfiI digestion. 
B2. Rep Cloning. pXR2 (Rep2Cap2) and pRep5Cap2 AAV helper plasmids served 
as templates for Rep cloning. The primer sequences used are indicated in Table 3. Two 
cloning strategies were used. Existing restriction sites were incorporated into primers for 
PCR (PCR-RD in Table 3) utilizing either pXR out fw or pXR out rev primers. PfuTurbo 
DNA Polymerase (Stratagene) was used at the manufacturer’s recommendations for all PCR 
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reactions. PCR-RD products were digested with the enzymes indicated in Table 3 (NEB) 
prior to ligation with T4 DNA Ligase (Invitrogen) according to manufacturer’s instructions. 
Alternately, an overlap-extension mediated PCR (OE-PCR) approach was used to produce 
Rep chimeras (39). The Rep2 and Rep5 junction was incorporated into forward and reverse 
primers which were used in separate PCR reactions with the pXR out fw and rev primers 
(Table 3, only fw oligos indicated, rev oligos complimentary to fw). These overlapping PCR 
products were combined into a single PCR reaction and cycled as follows: 1 cycle at 94oC for 
30 seconds, 18 cycles of 30 seconds at 94oC, 30 seconds at 65oC, and 4 minutes at 72oC, 1 
cycle of 10 minutes at 72oC. 1ul of this reaction was used as template for a nested PCR with 
the pXR in fw and rev primers. Chimeras with the N-terminus of Rep2 and C-terminus of 
Rep5 were cloned into the Rep25aa166 construct between the PpuMI and MfeI sites. 
Chimeras with the N-terminus of Rep5 and C-terminus of Rep2 were cloned into the 52aa160 
construct between the PpuMI and BstBI sites. All constructs were verified by DNA 
sequencing at the UNC-CH Genome Analysis Facility. 
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Clone/ 
Primer 
Cloning Method Orienta-
tion 
Sequence 
pXR out fw  Forward 5’CGAAAAGTGCCACCTGACGTCTAAGAAACC 
pXR in fw  Forward 5’TCGAATTCGACGGCCAGTGAATTGTAATACGACTC 
pXR out rev  Reverse 5’CCATGATTACGCCAAGCTCGGAATTAACCGCATGCG
A   
pXR in rev  Reverse 5’CCATGGCCGGGCCCGGATTCACC 
Rep52aa84 PCR-RD AleI Reverse 5’TTCACCCCGGTGGTTTCCACGAGCACGTGCATGTGG
AAGTAGCTCTCTCCCTTTTCAAACTGCACAAAG 
Rep52aa110 PCR-RD EagI Forward 5’CCTCGGCCGCTACGTGAGTCAGATTCGCGAAAAACT
GATTCAGAG 
Rep52aa126 OE PCR Forward 5’GTGGTCTTCCAGGGAATTGAACCCACTTTGCCAAAC
TGGTTCGCGGTC 
Rep52aa138 OE PCR Forward 5’CTGGGTCGCCATCACCAAGGTAAAGAAGGGAGGCG
GGAACAAGGTGGTGGATGAG 
Rep52aa146 OE PCR Forward 5’GCGGAGCCAATAAGGTGGTGGATGAGTGCTACATCC
CCAATTACTTGCTC 
Rep52aa160 PCR-RD Bpu10I Reverse 5’ACTGGAGCTCAGGTTGGACCTTCGGCAGCAGGTAG 
Rep52aa175 OE PCR Forward 5’CGTGGACAAACCTGGACGAGTATAAATTGGCCTGTT
TGAATCTCACGGAGCGTAAAC 
Rep52aa187   OE PCR Forward 5’CTGAATCTGGAGGAGCGCAAACGGTTGGTGGCGCAG
CATCTGACGCAC     
Rep52aa207 PCR-RD SgrAI Reverse 5’GATCACCGGCGCATCCGAGAACTCACGCTGCGAAGC 
Rep25aa77 OE PCR Forward 5’TAAGGCCCCGGAGGCCCTTTTCTTTGTGCAGTTTGAA
AAGGGATCTG 
Rep25aa97 OE PCR Forward 5’CCACATGCACGTGCTCGTGGAAACCTCCGGCATCTC
TTCCATGGTCCTCG 
Rep25aa116 PCR-RD NruI Forward 5’TCAGATTCGCGAAAAACTGGTGAAAGTGGTCTTCCA
GG 
Rep25aa125 OE PCR Forward 5’GAATTTACCGCGGGATCGAGCCGCAGATCAACGACT
GGGTCGCCATC 
Rep25aa141 OE PCR Forward 5’GGTCACAAAGACCAGAAATGGCGCCGGCGGAGCCA
ATAAGGTGGTGGATTCTGG 
Rep25aa149 OE PCR Forward 5’GAGGCGGGAACAAGGTGGTGGATTCTGGGTATATTC
CCGCCTACCTGC 
Rep25aa166 PCR-RD Bpu10I Forward 5’CCAGCCTGAGCTCCAGTGGGCGTGGACAAACCTG 
Rep25aa187   OE PCR Forward 5’GTTTGAATCTCACGGAGCGTAAACGGCTCGTCGCGC
AGTTTCTGGCAG 
Rep25aa216 PCR-RD SgrAI Forward 5’ATGCGCCGGTGATCAAAAGCAAGACTTCCCAGAAAT
ACATGG 
ITR2 Half1 Kpn  Forward 5’ATTATAGGTACCAGGAACCCCTAGTGATG 
ITR2 Half 1 Sfi  Reverse 5’TAATAGGGCCCAAAGGGCCGGG 
ITR2 Half2 Sfi  Forward 5’TTAATAGGCCCTTTGGGCCGGG 
ITR2 Half2 Hind  Reverse 5’ TATAATAAGCTTAGGAACCCCTAGTGATGGAG 
ITR5 Half1 Kpn  Forward 5’ ATTATAGGTACCTACAAAACCTCCTTGCTTGAG 
ITR5 Half1 Sfi  Reverse 5’TTAATAGGCCCTTTGGGCCGTCGC 
ITR5 Half2 Sfi  Forward 5’TTAATAGGCCCAAAGGGCCGTCGTC 
ITR5 Half2 Hind  Reverse 5’TATAATAAGCTTTACAAAACCTCCTTGCTTGAGAG 
Table 3. Oligonucleotides Utilized for Chimeric Rep Cloning. OE PCR indicates the oligo 
was used for the overlap extension method of cloning. PCR-RD indicates that PCR was 
performed and a restriction digest of the product was used for cloning. 
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B3. Western Blot Analysis. Samples for Western blot analysis were harvested 48-72 hours 
after transfection of Ad-helper plasmid and the appropriate AAV helper construct. Cells were 
washed and resuspended in 100ul PBS prior to addition of 100ul 2x Laemmli Sample Buffer 
(100mM Tris pH 6.8, 4% SDS, 200mM DTT, 20% glycerol, 0.1% Bromophenol Blue). 
Samples were briefly sonicated and boiled for 10 minutes. Samples were run on NUPAGE 4-
12% Bis-Tris gels (Invitrogen) at 160 volts for 90 minutes. Protein was transferred to a 
Nitrocellulose membrane (Invitrogen) via a wet transfer for 60 minutes at 30 volts. Gels were 
blocked overnight in 10% nonfat dry milk in 1x PBS/Tween (0.05%). Detection of both Rep2 
and Rep5 proteins (all four sizes) was achieved with a monoclonal Anti-Adeno-Associated 
Virus Rep Protein antibody (clone 259.5, American Research Products) at a 1:20 dilution in 
PBS/Tween for 60 minutes at room temperature. After washing, a secondary HRP anti-
mouse antibody was added at a 1:5,000 dilution in PBS/Tween for one hour at room 
temperature. After washing, SuperSignal West Femto Maximum Sensitivity Substrate 
(Pierce) was added and blots were exposed to X-ray film (Kodak).  
B4. Densitometry. Densitometry was performed using the public domain NIH Image 
program (developed at the U.S. National Institutes of Health and available on the Internet at 
http://rsb.info.nih.gov/nih-image/). Agarose gels stained with Ethidium Bromide were 
imaged and a DpnI-resistant cellular DNA was used as a loading control. Values from 
densitometric analysis vector replication of Southern blots were divided by values obtained 
from the loading control. The lowest value (absence of any vector replication) was then 
subtracted from all values as background. In order to gauge relative replication efficiency, 
values for replicating TR2 vectors were divided by the value obtained from the Rep2-ITR2 
control. Replicating TR5 vectors were similarly compared to the Rep5-ITR5 control.  
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B5. Molecular Modeling. Molecular models were generated using Swiss-Model 
(http://swissmodel.expasy.org). The published crystal structure of the amino-terminus of 
Rep5 complexed with the RBE (PDB accession #1rz9) was used as a template for all models. 
Visualization of protein structure rendering of images were performed with PyMOL 
(http://pymol.sourceforge.net). 
B6. Plasmid Construction. The N-terminus of Rep8 was synthesized by Gene Art 
AG (Regensburg, Germany). A PpuMI site was incorporated into the Rep8 sequence 31 bp 
from the transcriptional start site corresponding to the same site in Rep2. Synthesis ended at 
the BamHI site at residue 244 common to both serotypes. Rep8 sequence was cloned into the 
pXR2 (Rep2Cap2) backbone used for AAV helper plasmids to create the plasmid 
pRep82aa244. This plasmid was then used as a template for a PCR reaction with pXR out fw 
(5’ CGAAAAGTGCCACCTGACGTCTAAGAAACC) and Rep282 Bpu10I rev (5’ 
ACTGGAGCTCAGGCTGAGTCTTGGGCAGGAGGTAG). The PCR product was then 
digested with SfiI (common to Rep8 and Rep2) as well as Bpu10I (incorporated onto the 
Rep8 sequence using the primer) and cloned into the pXR2 backbone to create the clone 
Rep282aa73-163. 
3C. Results  
C1. Characterization of Chimeric ITRs. An alignment of ITR2 and ITR5 revealed 
several divergent elements which might infer Rep specificity (Figure 4). The RBE and 
hairpins seemed unlikely to impact specificity as Rep2 and Rep5 have been reported to bind 
ITR2 and ITR5 interchangeably (16). Additionally, no evidence has been presented for Rep 
interactions with the portion of the D-element outside the nicking stem. Therefore, the spacer 
and nicking stem elements appeared to be the most likely candidates for unique interactions 
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with their cognate Rep protein. This hypothesis was supported by low homology of these 
elements between AAV2 and AAV5.  
Wt ITRs containing the SfiI site functioned as expected with Rep2 specific to ITR2 
and Rep5 specific to ITR5 (Figure 13B). Rep2-ITR2 replicated approximately 2-fold more 
efficiently than Rep5-ITR5. This is potentially due to the lower folding energy of ITR5 
resulting in reduced plasmid stability prior to replication. Due to this minor difference in 
replicative fidelity, all ITRs replicated with Rep2 were normalized to Rep2-ITR2, while ITRs 
replicated with Rep5 were normalized to Rep5-ITR5 (Figure 13B). 
In order to confirm that the RBE and hairpin arms played no role in Rep specificity, 
we generated a chimeric ITR with ITR5 binding elements and an ITR2 spacer and nicking 
stem (ITR5+2SNS). Only Rep2 replicated this ITR, confirming the determinants of 
replicative specificity lie in the spacer/nicking stem elements (Figure 13B). While 
ITR5+2SNS replication was not as efficient as ITR2-Rep2, it was replicated at ITR5-Rep5 
levels. Conversely, Rep5 specifically replicated an ITR comprised of ITR2 hairpins and 
hairpin spacer and the ITR5 spacer and nicking stem (ITR2+5SNS, Figure 13B). Rep5 
replicated this ITR at wt levels. This data demonstrated that Rep-ITR specificity lies outside 
of the ITR binding regions.  
Next, we explored whether the nicking stem or the spacing between the RBE and 
nicking stem harbored unique interactions with the Rep protein by creating chimeric ITRs 
which divided these individual elements. An ITR with the ITR5 binding elements and spacer 
and the ITR2 nicking stem could not be replicated by either Rep2 or Rep5 (ITR5+2NS, 
Figure 13B). The corresponding chimeric ITR (ITR2 binding elements and spacer with an 
ITR5 nicking stem) was replicated by both Rep2 and Rep5 (ITR2+5NS, Figure 13B). This 
 65 
disparity suggested that the spacer and nicking stem play different roles in Rep-ITR 
specificity between AAV2 and AAV5. 
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Figure 13. Cloning and Characterization of Chimeric ITRs. 
(A) Sequence and structure of ITR2 (black) and ITR5 (blue) shown with incorporation of SfiI 
sites for cloning (green). Length in nt of ITR elements indicated above brackets. RBE is 
boxed. RBE’ is indicated by a hatched circle. Nicking stem is extruded with arrow indicating 
the nicking site and hatched box indicating the trs. The four initial chimeric ITRs generated 
are shown (right).  
(B) Replication assay and quantitation of chimeric Reps. Replication products from the 
indicated ITR and either Rep2 or Rep5 were analyzed by Southern blot. Monomeric (m) and 
dimeric (d) replicating species are indicated. The level of replication of each sample was 
measured by densitometric analysis and compared to wt replication.  
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C2. Nicking Stem Sequence and Height are Critical for ITR5 specificity. 
ITR2+5NS established that Rep2 is capable of nicking an ITR with an ITR5 nicking stem 
and that Rep-ITR specificity is not driven exclusively by the trs sequence (Figure 13B). In 
order to determine the flexibility of Rep2 toward mutant nicking stems, we generated ITR2s 
containing altered forms of the hairpin (Figure 14A). Rep2 is able to replicate an ITR with an 
ITR5 nicking stem even though the ITR5 nicking stem contains a different trs sequence, is 
one bp shorter, and has two fewer unpaired nucleotides at its tip (Figure 14A). The 
substitution of the ITR5 nicking stem into ITR2 also allowed replication by Rep5. 
To determine which element of the ITR2 nicking stem prevented Rep5 activity, we 
altered specific portions of the ITR2 stem. First, one bp at the top of the putative ITR2 
nicking stem was removed to lower the height to that of ITR5 (ITR2-TA). Removing the T-A 
bp also resulted in a trs resembling ITR5, nicking between G/T opposed to T/T. Rep2 
continued to function on this ITR as did Rep5, demonstrating that Rep5 can tolerate five 
unpaired nucleotides at the tip of the stem as long as the stem height and nt sequence are 
correct. A similar deletion from the base of the ITR2 nicking stem reduced the height to that 
of ITR5 while retaining the ITR2 nicking site (ITR2-GC). Rep2 continued to function 
efficiently on this ITR while Rep5 activity was ablated. This data suggested that the inability 
of Rep5 to function on ITR2 is primarily the sequence of the trs, specifically the requirement 
for a nick to be generated between G/T. 
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Figure 14. Relation of Nicking Stem Height and Sequence to Rep-ITR Specificity. 
(A) Sequence of nicking stem in an otherwise ITR2 context. Arrow indicates trs site. 
Brackets indicate height of putative stems in nt from the base of the stem to the putative 
nicking site. Predicted ΔG values for the hairpins are below. Southern blot analysis of the 
ITRs replicated by Rep2 or Rep5 is shown below.  
(B) Quantitation of the Southern blots relative to wt replication from (A).  
(C) Same as (A), except nicking stems indicated were used in an ITR5 context.  
(D) Quantitation of the Southern blots relative to wt replication from (C). 
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To determine the extent of Rep2 flexibility for different nicking stems, we created 
three additional ITR2 mutants. Extending the nicking stem by one bp at the base had no 
effect on replication by Rep2 (ITR2 9 nt). However, a three bp extension was sufficient to 
ablate Rep2 function on the ITR (ITR2 11 nt). Surprisingly, Rep2 was able to tolerate a three 
bp deletion from the base of the stem, underlining the flexibility of Rep2 with respect to 
nicking stem substrates (ITR2 5 nt).  
In order to explore the level of flexibility Rep5 possessed toward non-wt nicking 
stems, we created a panel of mutant ITR5s harboring altered nicking stems (Figure 14C). 
Curiously, Rep2 replicated none of these ITRs, suggesting an element outside the ITR5 
nicking stem is responsible for preventing Rep2 function. As in Figure 13B, replacement of 
the ITR5 nicking stem with that of ITR2 resulted in the ablation of replication by Rep5, 
attributable to the incompatible trs sequence. The addition of one bp at the top of the ITR5 
nicking stem severely decreased the ability of Rep5 to replicate the ITR (ITR5 +TA, Figure 
14D). This insertion disrupted the ITR5 trs sequence and increased the size of the stem one 
bp. However, the low level of replication by Rep5 on ITR5 +TA suggests that the entire trs 
site of ITR2 is necessary to confer Rep2 specificity, not just the presence of a T/T nick site. 
The addition of one bp to the base of the ITR5 nicking stem, preserving the ITR5 trs 
at the tip, nearly eliminated replication by Rep5 (ITR5 +GC). Likewise, the removal of one 
bp from the base of the ITR5 nicking stem strongly decreased replication by Rep5 (ITR5 6nt, 
Figure 14D). This data suggests that Rep5 is sensitive both to the height of the nicking stem 
as well as to the sequence of the trs. Thus, Rep5 is unable to replicate ITR2 because the ITR2 
nicking stem is one bp too tall and has an incompatible trs sequence. 
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C3. Spacer Length is Critical for ITR2, not ITR5. While Rep2 can replicate a 
vector with an ITR5 nicking stem, it can not replicate wt ITR5 (Figure 13B). The only 
difference between ITR5+2SNS (which Rep2 can replicate) and ITR5+2NS (which Rep2 can 
not) is the ITR5 spacer (Figure 13B). The wt Rep2 spacer is three nt long while the wt Rep5 
spacer is 15 nt long. Thus, we hypothesized that Rep2 may be sensitive to spacer length. 
Previous in vitro data supported this conclusion as insertions into the ITR2 spacer prevented 
nicking by Rep2 (10). 
To explore the effect of spacer length on ITR2 and ITR5, we generated a series of 
mutant ITR2s and ITR5s with differing spacer lengths (Figure 15A and 15C). An insertion 
extending the ITR2 spacer to 10 nt ablated replication by Rep2 (ITR2 10nt, Figure 3B). 
Similarly, substitution of the ITR2 spacer with the 15 nt spacer of ITR5 also ablated 
replication by Rep2 (ITR2 15nt, Figure 15B). Rep5 was unable to replicate any of these 
vectors due to the presence of the ITR2 stem loop. 
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Figure 15. Effect of RBE-Nicking Stem Spacing on Rep-ITR Specificity. 
(A) ITR2 mutants were synthesized with the indicated spacing between the RBE and nicking 
stem.   
(B) Southern blot analysis of the ITRs depicted in (A) replicated by either Rep2 or Rep5 
(Left). Quantitation of Southern blots relative to wt replication (Right).  
(C) ITR5 mutants synthesized as in (A).  
(D) Southern blot analysis and quantitation of (C).  
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Rep5 displayed greater flexibility toward spacer elements of differing lengths. 
Replacing the 15 nt ITR5 spacer with that of ITR2 resulted in an ITR which Rep5 retained 
the ability to replicate at a reduced level (ITR5 3nt, Figure 15D). Additionally, the presence 
of the three nt spacer allowed Rep2 to function on this ITR. The addition of six nt to the 
ITR5 spacer (for a total spacer length of 21nt) resulted in an ITR capable of being replicated 
by Rep5 at an efficient level (ITR5 21nt, Figure 15D). Replication by Rep5 was effectively 
abolished only after the insertion of 15 nt into the spacer (ITR5 30nt, Figure 15D). This panel 
of mutant ITR5s demonstrates the requirement for a three nt spacer element for Rep2 
function. 
This data confirmed that the length of the ITR5 spacer was critical to block Rep2 
function. Even small insertions into the ITR2 spacer were not tolerated by Rep2. Meanwhile, 
Rep5 is flexible in regard to spacer length, demonstrating the ability to function on ITRs with 
spacers from 3-21 nt. 
C4. The ITR5 Spacer Acts as a RBE for Rep5. The inability of Rep2 to function on 
ITRs with spacers longer than three nt led to the question of why Rep5 was so flexible in this 
regard. We hypothesized that Rep5 might specifically bind the ITR5 spacer just as it binds 
the RBE. The inability of Rep2 to bind this sequence would preclude its function on ITR5. 
Supporting this hypothesis was a moderately conserved GAGY Rep binding motif extending 
throughout the ITR5 spacer (Figure 16A). Additionally, as Rep monomers bind every four nt, 
the binding of three Rep5 monomers to the 15 nt spacer element would result in a three nt 
spacer, similar to that of ITR2 (38). 
If Rep5 does bind the loosely conserved GAGY motif, the removal of that motif from 
the spacer should abolish Rep5 function. Indeed, the ITR5 No GAGY mutant could not be 
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replicated by Rep2 or Rep5 (Figure 16B). This suggested that the specific sequence of the 
ITR5 spacer plays an active role in the Rep5-ITR5 interaction. Conversely, a spacer with a 
pure GAGY repeat should not disrupt the ability of Rep5 to function on the ITR. Indeed, 
Rep5 was able to replicate this ITR at wt levels (ITR5 GAGY, Figure 16B). Rep2 was also 
able to replicate this ITR efficiently, suggesting the poorly conserved nature of the GAGY 
repeat within the ITR5 spacer prevents a critical DNA-protein interaction with Rep2 
necessary for replication. 
To explore how the ITR5 spacer functioned as an RBE, we removed three GAGY 
repeats from the hairpin side of the RBE (ITR5 Spacer RBE, Figure 16A). This essentially 
shifted the 16 nt RBE 12 nt closer to the nicking stem. Rep5 replicated this ITR efficiently, 
confirming the ITR5 spacer acts as a RBE (ITR5 Spacer RBE, Figure 16B). The slight 
reduction in replication fidelity of this ITR with respect to wt ITR5 may signal the inability 
Rep to properly interact with the RBE’ (10). Rep2 was again unable to replicate ITR5 Spacer 
RBE due to its inability to interact with the ITR5 spacer. 
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Figure 16. The ITR5 Spacer Acts as a RBE for Rep5. 
(A) ITR5 mutants were synthesized with the indicated RBE and spacer sequence. Brackets 
indicate individual tetranucleotide repeats bound by Rep monomers. Both strands of the wt 
ITR5 sequence are shown to illustrate conservation with the GAGY motif (indicated by *). 
Only one strand shown on others.   
(B) Southern blot analysis of the ITRs depicted in (A) replicated by either Rep2 or Rep5 
(Left). Quantitation of Southern blots relative to wt replication (Right). 
(C) ITR2 mutants were generated with the RBE and spacer sequences indicated.  
(D) Southern blot analysis and quantitation for (C).   
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Next, we sought to extend the ITR2 spacer element to function as an extended RBE 
(Figure 16C). The seven nt insertion attempted in Figure 15A possessed essentially no 
GAGY homology (ITR2 +7, Figure 16C). As a result, Rep2 could not replicate this ITR 
(Figure 16D). Eight nt (two four nt GAGY repeats) inserted into the ITR2 spacer between the 
RBE and the existing spacer prevented replication by Rep2, demonstrating that the ITR2 
RBE can not be extended. 
Similar to ITR5 Spacer RBE, we retained the eight nt GAGY insertion into ITR2 
while removing eight nt of GAGY from the hairpin side of the RBE (ITR2 +8 -8, Figure 
16C). This shifted the RBE eight nt closer to the nicking stem. Rep2 replicated this ITR very 
inefficiently at a level below the detection threshold of densitometric analysis (Figure 16D, 
Southern). 
C5. Identification of Regions of Rep Responsible for ITR Specificity. Identifying 
the two elements of the ITR responsible for Rep specificity allowed us to map the regions of 
Rep2 and Rep5 involved in ITR specificity. We focused exclusively on the N-terminal 208 
aa of the large Rep proteins as this region encompasses the DNA binding and 
endonucleolytic activity of the protein (107). This region displays approximately 60% 
sequence conservation evenly distributed across the protein sequence (Figure 17A). Residues 
involved in the active site of the protein are 100% conserved between Rep2 and Rep5 (37). 
Residues implicated in binding the RBE’ are highly conserved (38). Residues which bind the 
RBE display nearly perfect conservation except for two conservative substitutions near aa 
140. 
In order to map the regions of Rep involved in ITR specificity, we generated a panel 
of chimeric Reps derived from Rep2 and Rep5 (Figure 17B). The ability of each chimeric 
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Rep to replicate an ITR2- or ITR5-flanked vector in HEK 293 cells was determined by 
Southern blot (Figure 17B and 17D). Each Rep in the panel was verified by DNA sequencing 
and Western blot analysis (Figure 17C). Every chimeric Rep showed similar protein 
expression profiles compared to wt. Densitometric analysis provided a comparison of the 
replication efficiency of each chimeric Rep with that of wt Rep2 or Rep5 (Figure 17E). 
Chimeric Reps were named according to the aa location of the swap between serotypes; for 
instance, Rep25aa77 possesses the N-terminal 76 aa of Rep2 and the C-terminus of Rep5.  
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Figure 17. Cloning and Characterization of Chimeric Reps. 
(A) An alignment of the N-termini of Rep2 and Rep5. (*) represents conserved amino acids. 
(: and .) indicates conservative substitutions. Blue indicates residues implicated in RBE 
binding interactions. Pink indicates residues which participate in the endonucleolytic active 
site. Green indicates residues implicated in RBE’ binding.  
(B) Chimeric Reps created and their ability to replicate ITR2 or ITR5 flanked vectors. 
Numbers indicate the aa position of the switch from one Rep to the other. (+) indicates the 
presence of replication, (–) indicates the absence.   
(C) Western blot for expression of the chimeric Reps. 
(D) Southern blot demonstrating replication of an ITR2 or an ITR5 vector by the chimeric 
Reps. Note that the ITR5 vector is 500bp larger than the ITR2 vector.  
(E) Level of replication of the chimeric Reps relative to wt Rep2 or Rep5.  
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In the case of Rep5, replacement of the N-terminal 77 or 97 aa with Rep2 had no 
effect on ITR specificity nor a significant impact on replicative fidelity (Figure 17D and 17E). 
Larger pieces of Rep2 substituted onto the N-terminus of Rep5 were sufficient to prevent 
efficient replication of ITR5s (Rep25aa116, Rep25aa125, and Rep25aa141). This suggested 
that these chimeras possessed interruptions of a critical region of Rep5 for ITR5 specificity. 
Rep2-based chimeras were unable to replicate ITR5s without the inclusion of the N-
terminal 146 aa of Rep5 (Rep52aa146, Figure 17D). Rep52aa146 replicated ITR5 at wt 
levels, as did the three chimeras with larger portions of Rep5 on the N-terminus (Rep52aa160, 
Rep52aa175, Rep52aa207). This mapping reveals that the critical region for ITR specificity 
in Rep5 lies between aa 97-146. Surprisingly, the Rep52aa146 clone also functioned 
efficiently on ITR2, constituting a Rep capable of replicating ITR2 and ITR5. This suggested 
that ITR specificity existed in two different regions of Rep. 
For Rep2, the N-terminal 83 or 109 aa of Rep5 could be substituted with no effect on 
ITR specificity or major influence on replicative fidelity (Rep52aa84 and Rep52aa110, 
Figure 17D and 17E). Chimeras including slightly larger portions of Rep5 were unable to 
replicate either ITR, again suggesting the interruption of a domain critical for ITR specificity 
(Rep52aa126 and Rep52aa138). Rep5-based chimeras were unable to replicate ITR2s 
without the inclusion of the N-terminal 149 aa of Rep2. However, ITR2 replication was 
inefficient (Figure 52aa149, Figure 17D and 17E). The inclusion of larger portions of Rep2 
allowed replication of ITR2s to increase to wt levels (Rep25aa166, Rep25aa216). This data 
maps the Rep2 region involved in ITR specificity to aa 110-149. However, unlike Rep5, this 
was not the only region which played a role in ITR specificity. The ability of the Rep52aa146 
chimera to replicate ITR2 and ITR5 vectors demonstrated a second region of Rep2 between 
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aa 138-160 sufficient to allow replication of ITR2s even when the other critical region (aa 
110-149) was Rep5. The isolation of two different Rep regions involved in ITR specificity 
was consistent with the discovery of two independent elements governing specificity within 
the ITR. 
C6. Characterization of Rep Regions Involved in ITR Specificity. To characterize 
the Rep domains identified in Figure 5, we created chimeric Rep proteins which specifically 
exchanged the regions implicated in ITR specificity (Figure 18A). Region 1 existed in Rep2 
from aa 110-149 and in Rep5 from aa97-146. Region 2 lay within Rep2 from aa 149-187 and 
Rep5 from aa 146-187. As in Figure 5, all chimeras were verified by DNA sequencing and 
Western blot analysis (Figure 18B). Chimeras were then assayed for the ability to replicate 
ITR2- or ITR5-flanked vectors (Figure 18C). 
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Figure 18. Characterization of Rep Regions Critical for ITR Specificity. 
(A) Chimeric Reps and their ability to replicate ITR2 or ITR5 flanked vectors. Numbers 
indicate the aa position of the switch from one Rep to the other. (+) indicates the presence of 
replication, (–) indicates the absence. Region 1 and 2 involved in Rep-ITR specificity are 
indicated.  
(B) Western blot for expression of chimeric Reps.  
(C) Southern blot demonstrating replication of an ITR2 or ITR5 vector by the chimeric Reps. 
Note that the ITR5 vector is 500bp larger than the ITR2 vector.  
(D) Structural model illustrating the two Rep regions. Rep2 structure is blue, Rep5 is purple. 
The nucleophilic tyrosine is indicated. Black hatched circle indicates the predicted structural 
difference of region 1 in the major groove of the ITR.  
(E) Structural model as in (D). The nucleophilic tyrosine is indicated.  
(F) Detailed structural view of region 1. The side-chains of non-conserved residues from 
Rep5 (purple) and Rep2 (blue) are shown. Three Rep5 residues implicated in RBE’ binding 
are indicated.  
(G) Detailed structural view of region 2. Side chains of active site residues are shown in 
black. Side chains of non-conserved residues in this region are shown for Rep2 (blue) and 
Rep5 (purple). The nucleophilic tyrosine is indicated, as is the adjacent Rep2 Asn-155.   
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Replacing Rep5 region 1 with Rep2 yielded a clone unable to replicate either vector, 
suggesting the chimera lacked the ability to bind the ITR5 spacer or nick the ITR2 nicking 
stem (Rep525aa110-148, Figure 18C). Replacing Rep5 region 2 with that of Rep2 allowed 
this chimera to replicate an ITR2 vector, suggesting region 2 of Rep2 was critical to nick the 
ITR2 nicking stem (Rep525aa146-187). The inability of this chimera to recognize ITR5 is 
harder to explain as Rep52aa146 could replicate ITR2 and ITR5 efficiently (Figure 17B). 
This result suggests that Rep2 region 2 makes specific contacts within Rep2 aa 188-208 
which are necessary in order to function on the ITR5 nicking stem. Replacing regions 1 and 2 
of Rep5 with Rep2 resulted in a Rep chimera which replicated only ITR2s (Rep525aa110-
187). 
Replacing Rep2 region 1 with Rep5 resulted in replication of only ITR2s, again 
demonstrating a connection between Rep2 region 2 and the ITR2 nicking stem (Rep252aa97-
146). The lack of ITR5 replication by Rep252aa97-146 is difficult to explain based on the 
Rep52aa146 chimera which replicates ITR2s and ITR5s efficiently (Figure 17B). This result 
suggests that Rep5 region 1 makes specific contacts within the preceding 96 aa of Rep5 
which are necessary in order to replicate ITR5. Replacing Rep2 region 2 with Rep5 resulted 
in a chimera unable to replicate either ITR (Rep252aa149-187). This chimeric Rep possesses 
neither Rep2 region 2 (required to nick the ITR2 nicking stem) nor Rep5 region 1 which 
appears necessary to interact with the ITR5 spacer. Finally, replacing both Rep2 regions 1 
and 2 with Rep5 resulted in a chimera capable of replicating only ITR5 vectors 
(Rep252aa97-187). 
The crystal structure of the N-terminal 193 aa of Rep5 complexed to the RBE allowed 
the location of these two critical regions to be modeled (38). The structure of the N-terminus 
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of Rep2 was modeled with Swiss-Model software using Rep5 as a template. The location of 
region 1 supports its involvement with the spacer/RBE (Figure 18D). This region interacts 
with the major groove of the ITR where one of the most apparent structural differences 
between Rep2 and Rep5 is predicted (Figure 18D, hatched circle). Rep2 contains a two aa 
insertion in this loop with respect to Rep5. This insertion and other non-conservative 
substitutions are likely responsible for the inability of Rep2 to interact with the ITR5 spacer. 
Viewing Rep along the length of the ITR illustrates that region 1 constitutes much of 
the base of the protein (Figure 18E). Both Reps are predicted to participate in a β-sheet motif 
in the center of this region, while areas of reduced homology exist toward either side (the 
loop interacting with the major groove of the ITR on one side, RBE’ interactions on the 
other). A more detailed look at region 1 reveals the greatest disparity between Rep2 and 
Rep5 occurs at the RBE binding interface in the major groove of the ITR (Figure 18F). 
There is very little predicted structural difference between region 2 of Rep2 and Rep5 
(Figure 18D and 18E). In an effort to dissect this region, we created two additional clones: 
Rep52aa147 and Rep52aa151 (Figure 18A). Like Rep52aa146, both of these Reps were able 
to replicate ITR2 and ITR5 vectors (Figure 18C). Rep52aa146 and Rep52 aa147 replicated 
ITR2 and ITR5 vectors with equivalent efficiency, suggesting E147 of Rep2 is not involved 
in ITR specificity. Rep52aa151 did display a modest reduction in ITR2 replication compared 
to Rep52aa146, suggesting that C151 of Rep2 plays a role in ITR2 specificity. Because 
Rep52aa160 can not replicate ITR2, this leaves only two other non-conserved residues 
between Rep2 and Rep5 in this region (N155 and T161). Both of these residues lie near the 
active site and are likely to interact with the nicking stem or active site. N155 lies directly 
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adjacent to Y156, the nucleophilic tyrosine, and may play a major role in ITR2 specificity 
(Figure 18G). 
C7. Comparison of Rep Region 1 across Serotypes. Finding two relatively small 
regions of the Rep protein important for ITR specificity allowed those regions in the other 
human/primate AAV serotypes to be analyzed in silico. An alignment of the two Rep regions 
in AAV serotypes 1-11 was performed by ClustalW analysis. Only Rep5 possessed a 
significant lack of conservation in Rep region 2 with respect to the other serotypes (data not 
shown). This suggests that all other AAV serotypes may have flexibility similar to AAV2 
toward the size and sequence of the nicking stem of the ITR. For region 1, however, there 
were three distinct groups (Figure 19A). Every serotype except AAV8 and AAV5 was highly 
conserved with AAV2. This supports previous reports of the inter-compatibility of serotypes 
1-4 and 6 in their Rep-ITR interaction (30, 31). Rep5 was significantly divergent from Rep2, 
accounting for the inability of Rep2 to bind the extended ITR5 RBE. Surprisingly, AAV8 
was poorly conserved in relation to both AAV2 and AAV5. Both the RBE’ and RBE binding 
interfaces of region 1 of Rep8 were poorly conserved, despite extremely high homology 
between the remainder of the N-terminus of Rep8 with Rep2 (Figure 19B). The C-terminus 
of the protein was also well conserved, suggesting that the differences in region 1 may 
contribute to a unique origin of replication for AAV8. Additionally, the co-crystal structure 
of Rep5 bound to its RBE allowed us to model the N-terminus of Rep8. These models 
suggested that Rep8 possessed unique structural confirmations in both the RBE and RBE’ 
interacting domains of Rep region 1 with respect to Rep2 and Rep5. This altered 
confirmation likely plays a critical role in ITR specificity (Figure 19C and D).  
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Figure 19. Alignment of Rep Region 1. 
(A) The majority of characterized AAV serotypes are highly conserved with AAV2 in Rep 
region 1. However, Rep5 and Rep8 display poor conservation to all other human/primate 
AAV serotypes in this region.  
(B) Homology between Rep2 and Rep8 along the full length of the Rep78 protein. Region 1 
of Rep8 (aa 113-141) is poorly conserved, sharing only 42% homology to Rep2 (cyan). The 
remainder of the N-terminus is highly conserved (yellow and green). The C-terminus is also 
well conserved (purple).  
(C and D) Structural models of the N-terminus of Rep2, Rep5, and Rep8. Rep8 (orange) is 
predicted to possess a significantly altered structure at the RBE binding interface of region 1 
(white arrow in C) as well as the RBE’ binding interface (white arrow in D).  
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Although the Rep8 sequence has been published, the ITR8 sequence has not. As we 
were unable to obtain the Rep8 construct, Gene Art AG (Regensburg, Germany) synthesized 
the N-terminal 244 aa. Rep chimeras were created with the N-terminal 244 aa of Rep8 and 
the C-terminus of Rep2 as well as a 50 aa section of Rep8 replacing Rep2 region 1 (Figure 
20A). The N-terminal 244 aa of Rep8 was also used with the C-terminus of Rep5 (data not 
shown). None of these chimeric Reps were able to replicate an ITR2 or ITR5 vector, 
suggesting that this region of Rep8 may confer specificity unique specificity to its cognate 
origin of replication with respect to all other AAV serotypes (Figure 20B).  
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Figure 20. Chimeric Rep8 proteins are not compatible with ITR2 or ITR5. 
(A) The Rep8-Rep2 chimeric proteins generated. (-) indicates the absence of replication on 
the indicated ITR. Numbers indicate the aa boundary of the chimera.  
(B) Southern blot showing replication of ITR2 and ITR5 vectors by Rep2 and the two Rep8 
chimeric constructs from (A). 
 
 
 94 
C8. Structure-Function Model of Rep-ITR Specificity. In order to unify the ITR 
and Rep elements involved in specificity into a single model, we utilized the chimeric Reps 
separating region 1 and region 2 along with the chimeric ITRs separating the nicking stem 
and spacer. Rep2, Rep5, Rep52aa146 (which divides region 1 and 2 of Rep and can replicate 
ITR2 and ITR5), and Rep25aa149 (essentially no ITR2 or ITR5 replication) were selected. 
These Reps were tested for their ability to replicate ITR2, ITR5, ITR2+5NS (which is 
replicated by both Rep2 and Rep5), and ITR5+2NS (which is replicated by neither Rep2 or 
Rep5). 
Only Rep2 and Rep52aa146 efficiently replicated ITR2 (Figure 21A and 21B). Only 
Rep5 and Rep52aa146 replicated ITR5. As in Figure 1, Rep2 and Rep5 replicated ITR2+5NS. 
Additionally, Rep25aa149 and Rep52aa146 replicated ITR2+5NS. This ITR is universally 
replicated by every Rep due to the exclusion of DNA elements involved in protein specificity. 
The three nt ITR2 spacer functions with the DNA binding region 1 of Rep2 or Rep5. The 
seven bp tall ITR5 nicking stem functions with region 2 of Rep2 or Rep5. Thus, any 
combination of these regions constitutes a Rep protein capable of replicating ITR2+5NS. 
Finally, neither Rep2 nor Rep5 replicated ITR5+2NS. Rep2 is unable to interact 
properly with the 15 nt ITR5. Rep5 is unable to function on the ITR2 nicking stem. For these 
reasons, Rep25aa149 was also unable to catalyze replication. However, Rep52aa149 was 
able to replicate this ITR due to the proper combination of Rep regions (Figure 21C). 
Rep52aa149 possesses Rep5 region 1 which is necessary to interact with the 15 nt ITR5 
spacer. This chimera also possesses Rep2 region 2, essential for function on the ITR2 nicking 
stem. This recombinant DNA-protein interaction is unique from either AAV2 or AAV5 and 
constitutes a novel Parvovirus origin of replication. 
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Figure 21. Model of Rep-ITR specificity. 
 (A) Southern blot of Hirt DNA demonstrating replication of the indicated ITR vector by the 
indicated Rep.  
(B) Table indicating the presence (+) or absence (–) of replication of the gel from (A).   
(C) Model of a novel AAV origin of replication. The chimeric ITR can be replicated only by 
a chimeric Rep protein. Rep5 sequence in region 1 (blue) is required for the extended RBE of 
ITR5 (purple). Rep2 sequence in region 2 (yellow) is required to function on an ITR2 nicking 
stem (cyan). 
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3D. Discussion 
Taken as a whole, this work illustrates two specific mechanisms of DNA-protein 
specificity at the Parvovirus origin of replication. Chimeric ITRs narrowed the DNA 
elements involved in specificity to the spacer and nicking stem sequences (Figure 13B). 
These results contradicted previous assertions that Rep-ITR specificity were driven solely by 
the nicking sequence as Rep2 efficiently nicked an ITR harboring the ITR5 nicking stem (16). 
Rep2 is highly flexible in the sequence and height of its nicking stem while Rep5 is highly 
specific to its cognate stem (Figure 14). 
Three residues of Rep2 are necessary to cleave the ITR2 nicking stem (Figure 17 and 
18). Residues C151, N155, and T161 all lie in the active site of the protein in a predicted 
alpha helix along with the nucleophilic tyrosine Y156. How these residues (termed Rep 
region 2) grant Rep2 flexibility toward mutant nicking stems remains unclear. The 
corresponding Rep5 residues (G148, A152, and V158) may participate in highly specific 
interactions which require specific height and sequence considerations for the ITR5 nicking 
stem.  
AAV5 Rep-ITR specificity is mediated by the ITR5 spacer. Replacement of the three 
nt ITR2 spacer with the 15 nt ITR5 spacer ablated replication by Rep2 (Figure 14B). A 
poorly conserved Rep binding element allows Rep5 to interact with the elongated ITR5 
spacer (Figure 16B). Mutating the spacer to include a strong Rep binding element allowed 
Rep2 and Rep5 to replicate the ITR. However, insertion of a Rep binding element into the 
ITR2 spacer still largely decreased Rep2 function. While this data might suggest that 
additional Rep5 molecules bind to ITR5, previous in vitro experiments have not come to this 
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conclusion, although those studies were performed in the absence of hairpins on the ITRs 
(16).  
A 49 aa region of Rep5 interacts with the ITR5 spacer (aa 97-146, Figure 17 and 18). 
The crystal structure of the N-terminus of Rep5 reveals that this region (region 1) possesses 
residues which specifically bind to the RBE and RBE’ of the ITR. Major structural 
differences in the Rep5 loop which binds the major groove of the RBE likely account for the 
majority of ITR5 spacer specificity. While Figure 1B predicts RBE’ binding should not play 
a role in Rep-ITR specificity, it is possible that RBE’ contacts alter the secondary structure of 
region 1 as it interacts with the RBE. 
Because the regions of Rep critical for ITR specificity were separate (region 1 of 
Rep5 from aa97-146 and region 2 of Rep2 from aa151-161), a chimeric Rep possessing both 
regions was able to efficiently replicate ITR2 and ITR5. An ITR which could be replicated 
by any wt or chimeric Rep was constructed by excluding the DNA elements required for 
specificity; the ITR5 spacer and the ITR2 nicking stem. Most significantly, a novel origin of 
replication was generated. This ITR contained both of the critical elements for Rep 
specificity; the ITR5 spacer and the ITR2 nicking stem. As a result, only a chimeric Rep 
protein made up of Rep5 region 1 and Rep2 region 2 was able to replicate the ITR. The 
creation of a unique origin of replication highlights the power of studying the DNA-protein 
interactions of a viral origin of replication. 
The creation of a unique DNA-protein interaction was possible because of the 
separation of the specific Rep-ITR interactions in AAV2 and AAV5. How and why these two 
different DNA-protein interactions evolved is unclear. It is likely due to evolutionary 
divergence in the ITR sequence which may have occurred in different hosts (AAV2 is related 
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to other primate AAVs, AAV5 is related to non-primate AAVs such as goat and bovine). 
This model of replicative specificity can likely be extended to other parvoviruses such as 
snake AAV which has a highly conserved T-shaped ITR structure but different spacer and 
nicking stem lengths (24). Similar DNA-protein interactions likely occur in distantly related 
viruses such as the autonomous human Parvovirus B19 which can have ITRs as long as 400 
bp (22). Less conserved Parvovirus origins of replication might also employ additional DNA-
protein interactions outside of the nicking stem and spacer sequences. 
Additionally, this work may provide further insight into why AAV2 is the only 
known animal virus capable of integrating site-specifically into the human chromosome (80). 
Integration occurs due to the specific cleavage of the AAVS1 site on chromosome 19 by 
Rep2. Rep2 is highly flexible in its nicking substrates, functioning on nicking stems from 
five bp to nine bp in height and on poorly conserved trs sequences. Thus, the only 
requirement for Rep2 to nick the human chromosome would be a functional nicking stem 
within three nt of a consensus RBE. As there are an estimated 2x105 consensus RBEs in the 
human chromosome, the likelihood of such an occurrence is high (108). This may also 
explain why an integration locus for AAV5 has not been identified. Rep5 is highly specific to 
both the height and sequence of the ITR5 nicking stem. There is likely no ITR5 nicking stem 
homolog in the human chromosome within range of a consensus RBE to allow nicking by 
Rep5. It is possible that other hosts infected by AAV5-related serotypes might possess 
chromosomal integration sites for AAV5.  
These results also stand to improve the safety of future AAV therapeutic vectors. The 
danger of AAV vector mobilization by wt AAV could be averted if therapeutic vectors 
harbored ITRs which no wt Rep could replicate (36). The mechanisms of Rep-ITR specificity 
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described here might extend to cellular elements. For instance, the C. elegans mobile element 
Tc1 contains terminal repeats which are specifically bound and endonucleolytically cleaved 
by its transposase, Tc1A (95). Biology at the related SV40 T antigen and papillomavirus E1 
origins of replication likely possess conserved interactions (37). Bacteriophage φX174 and 
plant geminiviruses, as well as other viruses which employ rolling circle mechanisms of 
replication also possess homology to the AAV origins of replication (43). In this way, 
dissection of specificity at the AAV origin of replication provides a broad platform to 
investigate other DNA-protein interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Methods to Prevent Vector Mobilization 
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4A. Introduction 
The creation of a novel AAV origin of replication resulted in three different vectors to 
test for anti-mobilization capabilities. While ITR5 flanked vectors should be at decreased risk 
of vector mobilization, they do not eliminate the underlying problem (36). The three 
remaining possibilities for mobilization resistant vectors are: Non-homologous ITR vectors, 
ITRs from non-human AAV serotypes, and a novel, lab-derived AAV origin of replication.  
While not complete in the prevention of vector mobilization, mixed ITR or non-
homologous ITR vectors should effectively remove all risk. Mobilization of a standard vector 
requires a cell to be triple-infected by a rAAV vector, a corresponding wt AAV serotype, and 
a helper virus. The inclusion of one ITR from a different serotype should require quadruple 
infection by the rAAV vector, two independent AAV serotypes, and a helper virus. 
Decreasing the risk further would be the natural tropism of the wt AAV serotypes (in this 
case, AAV2 and AAV5) which is unlikely to infect the same tissue as AAV2 and AAV5 
were isolated from completely separate cell types and use different cell receptors. If such a 
vector behaved as hypothesized, it would decrease the minor risk of vector mobilization to 
irrelevant levels.  
Better still is the promise of using unique AAV origins of replication from serotypes 
which do not infect humans. If such an ITR could be used to produce vector with their 
cognate Rep in human cells and package vector into the capsids from human/primate AAV 
serotypes, the risk of mobilization would be effectively eliminated. The only risk would be 
the unlikely occurrence of the non-human serotype jumping into and spreading through the 
human population.  
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While Chapter 3 provided evidence that the AAV8 origin of replication may be 
unique within the human/primate AAV serotypes, the ITRs are not readily available for the 
creation of new vector. Additionally, the isolation of AAV8 from primates would suggest the 
virus could jump into humans relatively efficiently (25). Therefore, we looked toward 
distantly related AAV serotypes, discovering that the complete genomic sequence of SAAV 
had been characterized (24). The snake ITR (sITR) varied substantially from the ITR of 
AAV2 and AAV5, as did the N-terminus of the snake Rep (sRep) protein. Thus, we chose 
the SAAV origin of replication for study.  
Finally, the findings in Chapter 3 resulted in the creation of a novel chimeric ITR 
which could be replicated only by a chimeric Rep protein made up of Rep2 and Rep5. 
Mobilization of this vector would require the quadruple infection of a cell with a rAAV 
vector, a helper virus, wt AAV2, wt AAV5, and a recombination event between AAV2 and 
AAV5 in a 42 nt region of the Rep protein. Therefore, if this novel origin can be adapted to 
an efficient vector production system, it will effectively negate any risk of vector 
mobilization by wt AAV.   
4B. Materials and Methods 
 B1. Plasmid Construction. Non-homologous ITR plasmids were constructed from 
the pTR2 or pTR5-eGFP constructs from Chapter 2. Each plasmid was double digested with 
AgeI and PciI which resulted in two fragments, each carrying a single ITR. The 
corresponding fragments were then ligated to create the plasmids pTR2-5 or pTR5-2 eGFP 
depending whether the 5’ ITR with respect to the GFP transgene was ITR5 or ITR2. The 
SAAV construct was a gift of Dr. Peter Tijssen. The sRepCap2 vector was created by overlap 
extension PCR. sRep was amplified using the primers 5’ ATATATGATGCGAGCAATGACGTC 
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AGCGGACATGTC and CTGGAAGATAACCATCGGCAGCCATATCTGTTATCAGTAAGTTTATTGTTC 
CTTGTCCAT. Cap2 was amplified with the primers 5’ ATGGACAAGGAACAATAAACTTACTGA 
TAACAGATATGGCTGCCGATGGTTATCTTCCAG and 5’ CCATGATTACGCCAAGCTCGGAATTA 
ACCGCATGCGA.  After overlap extension PCR, the sRepCap2 fragment was amplified by the 
nested primers 5’ ATATATCATATGAGCTCCAGC GGACATGTCTGGACATGTCTTTG and 5’ 
CCATGGCCGGGCCCGGATTCACC and inserted into pXR2 utilizing SacI and SacII. 
 B2. Transduction Assay. rAAV harboring ITR2, ITR5, or ITR5+2NS genomes were 
purified by a single CsCl gradient were titered by qPCR as in Chapter 2B. 5x104 HEK 293 
cells were infected by each virus at 10,000, 1,000, and 100 vg/cell. 48 hours post-infection 
cells were assayed visually to determine the extent of transduction.   
 B3. qPCR Titering for Mobilization. qPCR titering was performed as outlined in 
Chapter 2B. Cells harboring a persisting GFP encoding vector flanked by ITR2s, ITR5s, or 
ITR5+2NSs, were transfected with Ad-helper plasmid and either pXR2 (Rep2Cap2), 
pRep5Cap2, or pRep52aa149 (chimeric Rep specific to ITR5+2NS, Cap2). 48 hours later 
Hirt DNA was isolated and 10 ul was used in a qPCR reaction. 
4C. Results 
C1. Non-Homologous ITR Vectors. Vectors flanked by one ITR2 and one ITR5 
should require co-infection of wt AAV2 and AAV5 to be mobilized. Such vectors have been 
used to aid directional concatemerization of rAAV genomes; however, no account of their 
replicative efficiency or mobilization potential have been reported (104). In order to remain 
consistent with the results from Chapter 2, we utilized pTR2- and pTR5-eGFP to create two 
non-homologous ITR vectors (Figure 22A). These constructs differed by serotype of the ITR 
at the 5’ end of the GFP reporter gene. 
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Figure 22. Replication of non-homologous ITR vectors. 
(A) Two non-homologous ITR vectors were created with either ITR2 or ITR5 at the 5’ end of 
the GFP reporter gene. 
(B) Southern blot analysis of replicating non-homologous ITR vectors. The indicated ITR 
construct was co-transfected with Ad helper plasmid and the AAV helper plasmids listed. 
Hirt DNA was isolated and DpnI digested prior to Southern blot probed with labeled 
fragment corresponding to the GFP orf. Monomer (m) and dimer (d) replication 
intermediates are indicated.  
(C) Densitometery analysis of replication levels of TR5-2 vectors replicated by the Reps 
indicated. Replication was normalized to the Rep2-only replication of the vector. Analysis 
was performed in duplicate and standard error is indicated.   
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As Rep-ITR specificity appears consistent for replication and mobilization, the non-
homologous ITR vectors were first assayed for replication in the presence of Rep2, Rep5, 
both Rep2 and Rep5, as well as the chimeric Rep52aa149 capable of replicating ITR2 and 
ITR5 (Figure 22B). Forty-eight hours after transfection, Hirt DNA was isolated and assayed 
by Southern blot. Replicating monomer genomes were quantitated by densitometry analysis 
as in Chapter 3 (Figure 22C). These results verified that Rep2 or Rep5 alone was able to 
catalyze replication of the genome, though at a lower level than Rep2 and Rep5 in 
combination. In fact, the inclusion of both Reps increased the number of replicating genomes 
less than 1.5-fold. Rep52aa149 increased the number of replicated genomes by nearly 2-fold. 
That this Rep was slightly more efficient than Rep2 and Rep5 in combination may suggest a 
slight inhibitory effect of one Rep on the other. This may also be due to the decreased 
transfection efficiency of four plasmids (Ad helper, vector, Rep2 helper, Rep5 helper) into a 
single cell compared to three (Ad helper, vector, chimeric Rep).  
Despite the ability of a single Rep to efficiently replicate these vectors, we examined 
their utility as anti-mobilization tools. To do so, non-homologous ITR vector virus was used 
in the mobilization assay developed in Chapter 2. Twenty days after infection, GFP positive 
cells were sorted and pooled and persisting vectors were mobilized (data not shown). Not 
surprisingly, Rep2 or Rep5 alone were able to mobilize and replicate these genomes.  
While this data has implications for several aspects of AAV biology, it removes non-
homologous ITR vectors from consideration as anti-mobilization vectors. The ability of Rep2 
or Rep5 to replicate these vectors demonstrates that they are no different for anti-
mobilization purposes than the ITR2 or ITR5 flanked vectors tested in Chapter 2. Further, 
due to the incompatibility of the Rep-ITR interaction between AAV2 and AAV5, the ability 
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of these vectors to replicate efficiently in the presence of a single Rep suggests a gene 
correction event resulting in an ITR2 or ITR5 flanked genome.  
 C2. Snake AAV. Using the ITRs of non-human/primate AAV serotypes for AAV 
therapeutic vectors holds great promise in preventing AAV vector mobilization in humans. 
Due to almost perfect conservation with AAV5, the goat AAV origin of replication would be 
ineffective in the prevention of vector mobilization as Rep5 could likely rescue and replicate 
a goat-ITR vector. Alternately, the ITRs of the autonomous parvovirus B19 and several avian 
AAVs range from 400-600 bp in length and do not possess the T-shaped structure of human 
AAV (23). Such ITRs would further shrink the packaging capacity of AAV and may be too 
divergent to be encapsidated into human AAV capsids.  
The snake AAV origin of replication overcame most of these limitations. SAAV, 
isolated from Python regius and Boa constrictor snakes, has been fully sequenced (24). The 
snake Rep proteins (sRep) are only 37% conserved with Rep2 and 34% conserved with Rep5. 
The snake ITR (sITR) has a highly conserved secondary structure to ITR2 and ITR5; 
however, there is significant divergence in the nt sequence and the size/length of critical 
elements for Rep specificity (Figure 23A). The RBE and RBE’ sequences are reasonably 
conserved between serotypes, as is the hairpin spacer which separates them. This suggests 
that Rep2 and Rep5 may be able to bind sITR. However, there are major differences between 
all three serotypes in the ITR regions critical for specificity identified in Chapter 3. sITR 
contains an intermediate spacer length (12 nt) compared to ITR2 and ITR5. However, while 
Rep5 requires a partial GAGY consensus motif in its spacer, sITR has essentially no GAGY 
conservation in this element. This lack of a strong RBE in the spacer is likely to preclude 
Rep2 function on sITR. The sITR putative nicking stem is also significantly different from 
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that of ITR2 or ITR5, at only four nt in height and 12 nt in total length. This is likely to 
preclude Rep5 function which has specific requirements for both the height and sequence of 
the nicking stem.  
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Figure 23. Snake AAV possesses a unique origin of replication with respect to 
characterized human/primate AAV serotypes. 
 (A) Comparison of sITR with ITR2 and ITR5. The putative RBE is boxed. The putative 
nicking stem is shown extruded, and the putative nicking site is indicated by an arrow. The 
length of each segment is indicated above.  
(B) Schematic of sITR-GFP.  
(C) Southern blot of replication of sITR-GFP by the sRepCap2, Rep2Cap2, Rep5Cap2, and 
Rep6Cap6 helper plasmids. Replication of a replication deficient snake vector. Monomer (m) 
and dimer (d) replication intermediates are indicated. 
(D) sRepCap2 is unable to produce infectious vector as observed by a lack of transduction of 
HEK 293 cells (top). The addition of Rep2Cap2 rescues packaging of sITR-GFP producing 
vector which can efficiently transduce cells.   
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Thus, we created a GFP vector flanked by sITRs (Figure 23B). To determine whether 
sRep was able to encapsidate a sITR vector into a human capsid, we created a helper plasmid 
comprised of sRep and Cap2. Surprisingly, sRep was able to efficiently replicate the sITR-
flanked vector in HEK 293 cells with the human Ad-helper plasmid (Figure 23C). As 
predicted, Rep2, Rep5, and Rep6 were all unable to replicate the sITR vector.  
The inability of Rep2 and Rep5 to replicate sITRs confirmed their potential for 
preventing vector mobilization. However, efficient replication of the sITR vector by sRep 
was only the first step in vector production. The next step was to determine whether sRep 
could encapsidate the vector into Cap2. Infecting naïve 293 cells with lysate from cells 
transfected with sITR-GFP, sRepCap2, and Ad helper resulted in no GFP positive cells, 
suggesting vector was not produced (Figure 23D, top). Q-PCR results supported the 
conclusion that sRep failed to encapsidate the sITR vector into Cap2, as well as sCap (data 
not shown). A Western blot confirmed that sRepCap2 produced Cap2 as expected (data not 
shown). In an attempt to rescue encapsidation of the sITR vector, we added Rep2Cap2 along 
with sRepCap2. Lysate from this transfection contained infectious particles, effectively 
transducing naïve 293 cells. This results demonstrate that a chimeric SAAV-AAV2 sITR 
vector production system can be developed and should effectively prevent AAV vector 
mobilization.  
 C3. Novel Chimeric ITR as a rAAV Vector. The novel AAV origin of replication 
created in Chapter 3 has the potential to prevent AAV vector mobilization. Neither parent 
serotype (AAV2 and AAV5) can replicate the chimeric ITR. Thus, mobilization of this ITR 
would require a recombination even between Rep2 and Rep5 in order to reconstitute the 
chimeric Rep necessary to replicate the novel origin. First, the ability of the novel ITR 
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needed to be tested in a vector setting to assure functionality comparable to current vector 
production methods. For this purpose, this ITR5+2NS was compared to the DD forms of 
ITR2 and ITR5 to determine whether it could be used for vector systems.   
 The vector was prepared by the triple transfection of Ad-helper plasmid and either 
Rep2Cap2 with ITR2, Rep5Cap2 with ITR5, or Rep52aa149Cap2 with ITR5+2NS into five 
15cm plates. A CsCl gradient was used to purify the vector and the titer was determined by 
qPCR (28). The ITR2 and ITR5 vectors were both produced with equivalent titers as 
previously reported (36). The ITR5+2NS vector was consistently one to two orders of 
magnitude lower in titer than the wt ITRs (Figure 24A). This was consistent with the data 
from Chapter 3 suggesting the origin may replicate less efficiently than wt.  
 In order to determine whether the transduction efficiency of the novel ITR was also 
lower than wt, we infected HEK 293 cells with equivalent viral titers of the three vectors. 
Cells were infected with 10,000 vg/cell, 1,000 vg/cell, and 100vg/cell of each and the relative 
transduction efficiency of each was assessed (Figure 24B). All three ITRs demonstrated 
equivalent transduction potential by this assay, verifying that ITR5+2NS vectors are as 
infectious as ITR2 and ITR5 vectors. This suggests that ITR5+2NS vectors are stable and 
their low replication efficiency is a result of the Rep-ITR interaction, not the ITR itself.  
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Figure 24. Vector yields and transduction potential of a novel ITR. 
(A) Virus was purified via CsCl gradient and viral titer was measured by qPCR.  
(B) Viral vector was diluted in order to infect HEK 293 cells with the titer indicated. The 
vectors were flanked by the ITR and replicated by the Rep indicated. All were encapsidated 
into Cap2.  
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C4. Prevention of AAV Vector Mobilization by a Novel Chimeric ITR. While the 
vector production efficiency of the novel chimeric ITR might preclude it from widespread 
therapeutic use, its anti-mobilization properties could make it critical to the future of gene 
therapy. Additionally, while the vector yields are lower, the transduction efficiency is 
equivalent to the current ITR2 vectors that are widely used. In order to determine whether 
vectors flanked by this ITR are truly at a reduced risk of vector mobilization, we used the 
mobilization assay developed in Chapter 2 (Figure 26).  
HEK 293 cells were infected with 10,000 vg/cell of ITR2, ITR5, and ITR5+2NS 
flanked virus and passaged for 20 days. GFP positive cells were then sorted and pooled. The 
cell populations were grown out and remained 100% GFP positive. Each cell population was 
then transfected with Ad-helper plasmid and either no AAV helper, Rep2Cap2, Rep5Cap2, 
or Rep52aa149Cap2. Hirt DNA was isolated 48 hours later and 10 ul was used for qPCR 
with a primer set corresponding to the GFP coding sequence. Additionally, crude lysate was 
used to infect naïve 293 cells. 
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Figure 25. Specificity of the novel recombinant origin of replication extends to vector 
mobilization. 
(A) qPCR analysis of mobilized ITR2, ITR5, and ITR5+2NS GFP genomes from Hirt DNA 
isolated from cells mobilized with Ad-helper plasmid and the AAV helper indicated.  
(B) Lysate taken from cells containing mobilized genomes from (A) was used to infect naïve 
293 cells. Pictures were taken 48 hours after infection.  
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The ITR2 flanked genomes were efficiently mobilized by Rep2 (Figure 25A). Rep5 
resulted in no mobilization compared to background (Ad-helper only). Rep52aa149 gave 
modest mobilization of the ITR2 flanked transgene. The decrease in mobilization by 
Rep52aa149 with respect to Rep2 was supported by its ability to replicate an ITR2 flanked 
transgene with approximately 60% of Rep2 efficiency (Figure 17E). The ITR5 flanked 
genomes were efficiently mobilized only by Rep5 and Rep52aa149. The ITR5+2NS flanked 
genome could be mobilized only by Rep52aa149, supporting its possible utility as an anti-
mobilization vector. The transgene was not mobilized efficiently, likely due to the inability 
of Rep52aa149 to replicate it with wt efficiency. However, this decrease in mobilization 
efficiency would be beneficial when creating a mobilization resistant vector. While 
ITR5+2NS serves as an anti-mobilization vector, Rep52aa149 serves as a universal 
mobilization protein as it was able to mobilize ITR2, ITR5, and ITR5+2NS genomes. 
However, even if this Rep was reconstituted in nature, it would be unable to mobilize 
ITR5+2NS flanked vector genomes as efficiently as ITR2 or ITR5 flanked vectors. 
Transduction of mobilized vectors into naïve 293 cells supported the qPCR data (Figure 25B). 
Again, only Rep52aa149 was able to mobilize ITR5+2NS vector genomes. Rep52aa149 was 
also able to mobilize ITR2 and ITR5 vectors, though mobilization of ITR2 and ITR5+2NS 
genomes was inefficient, resulting in very few visible GFP positive cells.  
4D. Discussion 
 The assays developed in Chapter 2 yielded the tools to test novel vectors which might 
prevent AAV vector mobilization in humans. While conceptually well-founded, the use of 
non-homologous ITR vectors was obviated by the nature of the ITR itself. The inability of 
the Rep2 or Rep5 to work on the ITR of the opposite serotype has been well established 
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previously and in this work (16). That Rep2 or Rep5 alone can replicate these vectors 
efficiently suggests that they are actively being converted into homologous ITR vectors upon 
transfection. This is almost certainly due to the ability of one ITR to serve as a template to 
repair the opposite one (79). This is so efficient that the use of a chimeric Rep capable of 
replicating each ITR type only increased the amount of replicated genomes by 2-fold. This 
suggests that of the genomes replicated by the chimeric Rep, half have likely undergone ITR 
repair to become homologous ITR vectors.  
Due to these considerations, the ability of a single Rep to mobilize these genomes 
from cells was not surprising. What is quite striking, however, is the rate at which one ITR 
can be used to repair/replace the other. This has likely arisen out of necessity due to the latent 
phase which AAV must enter in the absence of helper virus. Either mode of AAV genomic 
persistence (circularization/concatemerization and chromosomal integration) requires that the 
ITR undergo recombination. This often results in partial deletion of the ITR, especially with 
respect to chromosomal integration thought to occur using homologous recombination 
through microhomologies anywhere in the ITR (75). Thus, the ability of AAV to repair itself 
as it enters the lytic cycle is critical for the survival of the virus. It is possible that the ability 
to repair the ITR is the selective force which has led to the evolution of such a 
recombinogenic structure.  
The use of non-human AAV ITRs to prevent vector mobilization posed a number of 
obstacles. First, the Rep protein needed to be efficiently expressed in a functional state in 
human HEK 293 cells. Additionally, due to the lack of a species-specific Ad-helper, the viral 
genes needed to be efficiently complemented by human Ad. The ITR needed to be divergent 
enough from the human/primate ITRs so that the human Reps could not catalyze its 
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replication; however, the ITR needed to be conserved enough to be packaged into 
human/primate Cap required for current rAAV vectors.   
By these criteria, SAAV shows enormous promise in the prevention of vector 
mobilization. The virus can efficiently replicate in human-derived cells with human-derived 
Ad-helper genes, despite its reptilian lineage and poor homology to primate AAVs. Critically, 
the sITR can not be replicated by Rep2, Rep5, or Rep6. Unfortunately, sRep is unable to 
package an sITR vector into Cap2 or sCap. The inability of sRep to encapsidate the vector 
into its cognate Cap suggests either a mutation in the sRep or sCap construct or that SAAV 
encapsidation needs to occur in reptilian cells or in the presence of Snake Ad. However, the 
addition of Rep2 rescued sITR encapsidation. It is unclear whether Rep2 is interacting with 
the SAAV replication machinery or is binding and encapsidating replicated ss sITR-flanked 
genomes. In either case, we now possess a sITR vector production system ready for 
optimization and incorporation into rAAV applications.  
Perhaps the ultimate method for preventing vector mobilization comes not from 
optimizing current AAV origins of replication but from creating entirely new Rep-ITR 
interactions. While the use of a non-human/primate AAV will always carry the risk of that 
same non-human serotype jumping into our species, a novel recombinant ITR would possibly 
be unable to be replicated by any naturally occurring AAV in existence. Chapter 3 describes 
the creation of such a novel origin of replication. 
Unfortunately, while the novel origin is possesses a unique Rep-ITR interaction with 
respect to its parent serotypes, it also lacks the replicative efficacy of its parents. Vector 
preparations using this ITR were consistently one to two orders of magnitude lower in titer 
than ITR2 or ITR5 vectors. In a therapeutic setting where current ITR2 vectors are often 
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limited by the titer that can be achieved, 10-100 times lower titer would prevent the use of 
any vector. However, the recombinant ITR displays the same transduction efficiency as ITR2 
or ITR5 vectors. This demonstrates that the rate limiting step for ITR5+2NS is vector 
production efficiency, and if that shortcoming be addressed, it could likely serve as the ITR 
in all future vector applications.  
The same decreased interaction between the recombinant ITR and recombinant Rep 
also explains the low degree of vector mobilization of this ITR seen in Figure 25A. Only 
Rep52aa149 can mobilize ITR5+2NS at any level. Even then, rescue and replication of the 
vector is so weak that even if a recombination event in nature produced a Rep52aa149-like 
Rep, the chance of it leading to sustained mobilization of the vector is exceedingly low. 
Between the promise of this vector and the potential shown by non-human ITRs, the risk of 
vector mobilization can be eliminated by the time rAAV vectors are ready to progress 
beyond clinical trials.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Future Directions 
 
 
 
 
 
 
 
 
 
 
 
 
 122 
Future Directions 
The number of individuals in the population carrying a rAAV vector stands to 
increase dramatically as AAV-mediated gene delivery progresses further into the clinic. 
Current clinical trials have seen rAAV vectors administered to nearly every major organ in 
the body. As these treatments become mainstream, the risk of these ITR2 flanked vectors 
being mobilized by an Ad/AAV infection will only grow.  
By characterizing the AAV origin of replication, we have taken the first steps towards 
circumventing the risks posed by vector mobilization. Determining the mechanisms of DNA-
protein specificity in the Rep-ITR interaction has also unlocked new questions about the 
AAV origin of replication. The only human/primate AAV serotype (apart from AAV5) with 
significant divergence in Rep homology from Rep2 is AAV8. Chimeric Rep8-Rep2 proteins 
failed to replicate ITR2 or ITR5, suggesting AAV8 may have a novel origin of replication 
with respect to the other AAV serotypes. The determinants of this specificity should be 
readily determined upon the publication of the ITR8 sequence. Rep8-ITR8 specificity will 
likely exist within the spacer/nicking stem regions of the ITR, just as it does in AAV2 and 
AAV5. However, the AAV8 origin may possess a unique Rep-ITR interaction outside this 
section of the ITR, potentially deriving specificity from the RBE’.   
Further biochemical and structural studies are needed to define the individual 
determinants of Rep-ITR specificity. Several residues seem particularly critical in this regard. 
Such studies are necessary to identify the specific Rep interactions with both the nicking 
stem and spacer of the ITR. Additional studies are also needed to explore the function of Rep 
region 1. This region possesses interactions with both the RBE and RBE’ of the ITR. 
Because a single Rep molecule can not be bound to RBE, the RBE’, and interact with the 
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nicking stem, it is unclear why the RBE’ portion of Rep region 1 impacts the RBE binding 
and nicking function of the protein. Nonetheless, in order for any Rep to function on any ITR, 
the RBE and RBE’ interacting domains of region 1 must originate from the same serotype.  
As Rep is able to function on ITRs lacking the RBE’ and hairpins entirely, this observation is 
likely due to proper folding of the Rep protein (16).  
Additionally, this work has implications with respect to AAV site-specific integration. 
AAV2 can direct integration of its genomes into the AAVS1 site of human chromosome 19. 
This occurs because the chromosome contains a RBE and a trs on the chromosome which 
can be nicked by Rep2 (80, 97). Rep2 is believed to nick and unwind the chromosome at the 
trs, resulting in the recruitment of host repair machinery. AAV genomes are then inserted 
into the chromosome through mini-homologies within the ITR via the homologous 
recombination pathway. The ability of other AAV serotypes to integrate into the AAVS1 site 
has not been characterized. However, high conservation between AAV2 and AAV serotypes 
1-4, 6, 7, and 9-11 suggests that these serotypes should be capable of targeted integration into 
the same site.    
Attempts to discover a human chromosomal integration locus for AAV5 have been 
unsuccessful. It is likely that the determinants of Rep5-ITR5 specificity identified in Chapter 
3, specifically the sensitivity to changes in the nicking stem, are responsible for the absence 
of Rep5 nicking sites in the human chromosome. However, having identified these 
requirements, it should be possible to engineer an AAV5 targeted integration site into human 
cell lines. The ability to achieve differential Rep-mediated targeted integration of a vector 
into different sites dependent on the Rep supplied would impact therapeutic endeavors as 
well as biotechnological methods. It is also possible that the chromosomes of non-human 
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organisms which harbor closely related AAV serotypes (goat, bovine), possess AAV5 
integration sites. While the likelihood of identifying such a site is unlikely through homology 
searches (AAVS1 is poorly conserved with ITR2), directed integration studies with goat or 
bovine cell lines may yield a novel site for site-specific AAV5 integration.  
Initial data indicates that SAAV holds the potential to eliminate the risk of vector 
mobilization. The sRep-sITR interaction is unique with respect to human AAV serotypes, yet 
SAAV vectors can be replicated in human cells with human Ad-helper. It is unknown 
whether sRep can encapsidate sITR vectors directly into human/primate capsids, or whether 
a chimeric Rep possessing the sRep N-terminus and Rep2 C-terminus will be required. The 
relative vector yields of a SAAV production system will need to be comparable to those of 
the current AAV2 based vectors. Additionally, the relative integration efficiency of sITR 
compared to ITR2 or ITR5 must be determined to insure that SAAV vectors are safe. Also, 
because the SAAV origin of replication is unique with respect to AAV2 and AAV5, the 
existence of a possible SAAV site-specific integration locus in the human chromosome must 
be determined. Finally, the mobilization assays described in Chapter 2 must be repeated to 
demonstrate the increased safety potential of sITRs.  
Perhaps the most significant result of this work was the creation of a novel AAV 
origin of replication. This recombinant ITR provides the greatest means to eliminate the risk 
of vector mobilization. However, several steps lie between it and the clinic. The depressed 
vector yields achieved with this ITR must be improved. Because the use therapeutic rAAV 
vectors is often limited by titer, a log-order decrease in the titer of any vector with respect to 
an ITR2 vector would make it impractical for clinical purposes. Directed evolution or 
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rational mutagenesis of this novel ITR is necessary in order to generate an origin of 
replication with wt AAV levels of replicative fecundity. 
If the vector yields can be increased, this novel ITR must be fully characterized 
before it can enter the clinic. We have already demonstrated that the relative transduction 
efficiency, adjusted for titer, of this ITR is equivalent to ITR2 and ITR5. The random 
integration potential of this ITR must be explored and shown to be equivalent to its parent 
serotypes, AAV2 and AAV5. The ability of this ITR to undergo site-specific integration 
should also be explored. The chimeric Rep specific to this ITR also functions on ITR2 (albeit 
at a lower than wt efficiency) and should still recognize the AAVS1 site of chromosome 19. 
Thus, this novel origin may still undergo site-specific integration into AAVS1 at some level. 
Additionally, Rep52aa146 may be able to direct rAAV vectors into a separate site in the 
chromosome. This chimeric Rep possesses AAV2-like flexibility toward nicking stem 
substrates as well as the binding promiscuity of Rep5. Thus, it is entirely possible that a 
location for site-specific integration of ITR5+2NS already exists in the human chromosome.  
The driving force behind these experiments was the clinical risk of vector 
mobilization. Of all the methods tested to prevent mobilization, the most successful came out 
of studying the basic biology of AAV. In that way, this work straddled both the clinical and 
virological aspects of AAV. Future experiments are likely to walk a similar path. Through its 
evolution, AAV has been faced with many of the same challenges which complicate the use 
of rAAV vectors today. Studying nature’s solutions stands to have a greater impact on the 
future of AAV-mediated gene delivery than any rational engineering approach. 
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Appendix 1: Chimeric and Mutant Rep Proteins Created 
 
Name Description 
Replicates 
ITR2 
Replicates 
ITR5 
Confirmed by 
Western 
Rep52aa73  Yes No Yes 
Rep52aa84 Described in Chapter 3 Yes No Yes 
Rep52aa110 Described in Chapter 3 Yes No Yes 
Rep52aa126 Described in Chapter 3 No No Yes 
Rep52aa138 Described in Chapter 3 No No Yes 
Rep52aa146 Described in Chapter 3 Yes Yes Yes 
Rep52aa147 Described in Chapter 3 Yes Yes Yes 
Rep52aa151 Described in Chapter 3 Yes Yes Yes 
Rep52aa156  No Yes Yes 
Rep52aa160 Described in Chapter 3 No Yes Yes 
Rep52aa175 Described in Chapter 3 No Yes Yes 
Rep52aa207 Described in Chapter 3 No Yes Yes 
Rep25aa73  No Yes Yes 
Rep25aa77 Described in Chapter 3 No Yes Yes 
Rep25aa89  No Yes Yes 
Rep25aa97 Described in Chapter 3 No Yes Yes 
Rep25aa116 Described in Chapter 3 No Yes (low) Yes 
Rep25aa125 Described in Chapter 3 No Yes (low) Yes 
Rep25aa136  No Yes (low) No 
Rep25aa141 Described in Chapter 3 Yes Yes (low) Yes 
Rep25aa149 Described in Chapter 3 Yes No Yes 
Rep25aa166 Described in Chapter 3 Yes No Yes 
Rep25aa187  Yes No No 
Rep25aa216 Described in Chapter 3 Yes No Yes 
Rep25aa244  Yes No Yes 
Rep25aa101  No No No 
Rep25aa116K100S K100S does not rescue Rep25aa116 No Yes (low) No 
Rep2 K72A Contradicts previous findings (93) Yes No Yes 
Rep5 K72A  No Yes Yes 
Rep2 C179A Determining importance of Rep2 C179 No No No 
Rep52aa146 C179A Determining importance of Rep2 C179 Yes Yes No 
Rep525aa110-148 Described in Chapter 3 No No Yes 
Rep525aa146-187 Described in Chapter 3 Yes No Yes 
Rep525aa110-187 Described in Chapter 3 Yes No Yes 
Rep525aa136-146  No No No 
Rep252aa97-146 Described in Chapter 3 Yes No Yes 
Rep252aa149-187 Described in Chapter 3 No No Yes 
Rep252aa97-187 Described in Chapter 3 No Yes Yes 
Rep252aa136-141  Yes No No 
Rep82aa244 Described in Chapter 3 No No Yes 
Rep282aa113-163 Described in Chapter 3 No No Yes 
Rep85aa163  No No No 
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Appendix 2: Chimeric and Mutant ITRs Created 
 
Name Description 
Replicated 
by Rep2 
Replicated 
by Rep5 
ITR2 ITR2 in DD format w/ SfiI site for cloning Yes No 
ITR5 ITR5 in DD format w/ SfiI site for cloning No Yes 
ITR5+2NS 
ITR5 with ITR2 nicking stem - Replicated only by 
Rep52aa149 No No 
ITR2+5NS ITR2 with ITR5 nicking stem Yes Yes 
ITR2+7 ITR2 with 7bp spacer insertion No No 
ITR5+6 ITR5 with 6bp spacer insertion No Yes 
ITR5+15 ITR5 with 15 bp insertion in the spacer No No 
ITR2-TA ITR2 with T-A bp deleted from top of nicking stem Yes Yes 
ITR5+2SNS ITR5 with ITR2 spacer and nicking stem No No 
ITR5+2S ITR5 with ITR2 spacer Yes Yes 
ITR5+TA ITR5 with T-A bp insertion at top of nicking stem No Yes 
ITR2 Crowfoot ITR2 with extra RBE hairpin (for a total of three) Yes No 
S1 ITR 
ITR2 with the RBE, spacer, and nicking stem of the 
AAVS1 site on Chromosome 19 Yes No 
ITR5-GC ITR5 with G-C bp deleted from base of nicking stem No Yes 
ITR2+GC ITR2 with G-C bp inserted into base of nicking stem Yes No 
ITR5+2SNS-GGG 
ITR5 with ITR2 nicking stem and spacer with a three 
nucleotide deletion from the hairpin spacer Yes No 
ITR2 No Stem ITR2 with the nicking stem deleted No No 
ITR2 Reconstituted 
Stem ITR2 with nicking stem but mutant trs sequence No No 
ITR5 No Stem ITR5 with the nicking stem deleted No No 
ITR5 Reconstituted 
Stem ITR5 with nicking stem but mutant trs sequence No Yes (low) 
S1 ITR No hairpins 
AAVS1 P1 element cloned with an SfiI site and no 
RBE' Yes No 
ITR2-2ntRBE 
ITR2 with spacer and first two nt of the RBE deleted 
which supports AAVS1 nicking stem Yes No 
ITR2+5SNS ITR2 with an ITR5 spacer and nicking stem Yes No 
ITR2+5SNS+GGG 
ITR2 with an ITR5 spacer and nicking stem and three 
nt (GGG) inserted into the hairpin spacer No No 
ITR5 No GAGY ITR5 with the GAGY from the spacer removed No No 
ITR5 GAGY ITR5 with perfect GAGY homology in the spacer Yes Yes 
ITR5 Spacer RBE 
ITR5 with GAGY consensus in the 12nt of the RBE 
nearest the hairpins removed No No 
ITR2 +8 GAGY 
ITR2 with 8nt spacer insertion with perfect GAGY 
homology No No 
ITR2 +8-8 GAGY 
ITR2 with 8nt spacer insertion with perfect GAGY 
homology and 8nt of GAGY homology removed from 
the RBE nearest the hairpins Yes No 
ITR5 No Hairpins ITR5 with no hairpins (for RBE') No No 
ITR2-GC ITR2 with one bp removed from the base of the stem  Yes No 
ITR2 5bp ITR2 with 5bp tall nicking stem and conserved trs Yes No 
ITR2 11bp ITR2 with 11bp nicking stem and conserved trs No  No 
ITR5 5bp 
ITR5 with 5bp tall nicking stem (deletions from 
nicking stem base) No Yes 
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ITR5 9bp 
ITR5 with 9bp tall nicking stem (insertions at base of 
stem) No Yes 
ITR5+GC 
ITR5 with G-C bp inserted into the base of nicking 
stem No Yes 
ITR5+2NS-GC 
ITR5 with an ITR2 nicking stem with a GC bp deleted 
from the base of the nicking stem No No 
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